document incorporate reference document proxy statement annual meeting iii shareholder hold file securities exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum financial statement note consolidated financial statement report independent register public accounting firm supplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature consent independent register public accounting firm table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel financial information information company segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner overview merck continue execute strategic priority despite face business challenge include august patent expiration singulair montelukast medicine indicate chronic treatment asthma relief symptom allergic rhinitis worldwide sale billion decline compare include unfavorable effect foreign exchange exclude impact foreign exchange sale increase reflect growth key product key geographic region offset impact singulair patent expiration company reduce operating expense efficiently manage cost target reduction addition company generate new clinical datum advance certain key research development pipeline program company fourpart growth strategy focus execute core business include large market core brand new launch brand research development effort target therapeutic area great future patient demand scientific opportunity expand geographically highgrowth market extend complementary business consumer care animal health effectively manage cost continue invest future growth begin company sale performance large market despite adverse effect singulair patent expiry cause significant rapid decline singulair sale sale united states relatively flat compare prior year reflect strong growth key brand include januvia sitagliptin janumet sitagliptinmetformin hci treatment type diabete zostavax zoster vaccine live vaccine help prevent shingles herpe zoster gardasil human papillomavirus quadrivalent type vaccine recombinant vaccine help prevent certain disease cause type human papillomavirus hpv victrelis boceprevir treatment chronic hepatitis isentress raltegravir antiretroviral therapy use combination therapy treatment hiv infection turn europe canada company continue experience positive volume growth trend key table content brand include victrelis januvia janumet simponi golimumab treatment inflammatory disease growth partially offset increase generic erosion price decline stem economic issue relate fiscal austerity measure region respect research development effort company continue advancement drug candidate pipeline company currently candidate review food drug administration fda suvorexant investigational treatment insomnia sugammadex sodium injection medication reversal certain muscle relaxant surgery mkc investigational combination ezetimibe atorvastatin treatment primary mixed hyperlipidemia vintafolide investigational cancer candidate review european union addition company currently candidate phase iii development anticipate file new drug application nda biologics license application bla applicable fda respect candidate december company announce hpsthrive heart protection study treatment hdl reduce incidence vascular event study tredaptive extendedrelease niacinlaropipant meet primary endpoint result company plan seek regulatory approval medicine united states january merck begin take step suspend availability tredaptive outside united states february company announce recently receive review safety efficacy datum phase iii study involve odanacatib company investigational treatment osteoporosis postmenopausal woman result review datum company conclude review additional datum previously plan ongoing extension study warrant filing application approval fda delay previously announce company conduct blinded extension trial approximately woman provide additional safety efficacy datum merck anticipate file application approval odanacatib additional data extension trial company continue believe odanacatib potential address unmet medical need patient osteoporosis merck continue pursue opportunity establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound technology platform potential drive near longterm growth company complete variety transaction span different therapeutic area clinical stage include licensing agreement endocyte inc endocyte vintafolide investigational cancer candidate aicuris portfolio investigational medicine target human cytomegalovirus include letermovir consistent second element company strategy expand geographically highgrowth market japan key emerge market company continue invest market emerge market sale grow include unfavorable impact foreign exchange despite loss sale remicade infliximab simponi treatment inflammatory disease market relinquish johnson johnson arbitration settlement agreement discuss china continue important growth driver sale exceed billion represent growth prior year include favorable effect foreign exchange growth japan temper generic competition biennial price cut early year merck enter transaction design strengthen presence emerge market long term company joint venture simcere pharmaceutical group china begin preliminary operation late component merck strategy relate complementary business consumer care animal health merck animal health business continue solid contributor revenue growth include unfavorable effect foreign exchange reflect growth cattle poultry companion animal swine product line sale consumer care product grow include unfavorable effect foreign exchange lead scholl franchise high sale coppertone miralax claritin note element company strategy tightly manage cost invest growth consistent effort merck remain committed drive continuous productivity improvement enterprise continue realize cost saving area company saving result table content action include merger restructuring program discuss previously announce ongoing cost reduction activity non restructuringrelated activity end company achieve project billion annual net cost saving activity merger scheringplough corporation scheringplough merger global restructuring program initiate conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company workforce reduction associate plan relate elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company record total pretax restructuring cost million billion billion relate program cost associate company restructure action include material production cost market administrative expense research development expense restructure cost restructuring action merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate subsequent merger company rationalize number manufacture site worldwide remain action program result additional manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion billion company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect merger restructure program yield annual saving end approximately billion billion annual saving completion program approximately billion billion november mercks board director raise company quarterly dividend share share february merck reach agreement principle plaintiff resolve federal security classaction lawsuit pende district court district new jersey merck scheringplough certain current officer director enhance litigation propose agreement merck pay million resolve security class action merck defendant million resolve security class action scheringplough defendant connection settlement merck record pretax aftertax charge million reflect million anticipate insurance recovery earning common share assume dilution attributable common shareholder eps reflect net unfavorable impact result acquisitionrelate cost restructure cost charge relate enhance litigation note nongaap eps exclude item nongaap income nongaap ep table content product sale sale company product follow million primary care women health cardiovascular zetia vytorin diabetes obesity januvia janumet respiratory singulair nasonex clarinex dulera asmanex womens health endocrine fosamax nuvare follistim implanon cerazette maxalt arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress pegintron cancida victrelis invanz primaxin noxafil oncology temodar emend cosopttrusopt bridion integrilin diversify brand cozaarhyzaar propecia zocor claritin remeron proscar vasotecvaseretic vaccine gardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately reflect nonreportable segment animal health consumer care alliance alliance segment include revenue company relationship azlp revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder certain product company franchise follow primary care women health cardiovascular zetia market ezetrol outside united states vytorin ezetimibesimvastatin market inegy outside united states cholesterol modifying medicine diabetes obesity januvia janumet treatment type diabete respiratory singulair nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptom clarinex desloratadine nonsedate antihistamine dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma asmanex twisthaler mometasone furoate inhalation powder inhale corticosteroid firstline maintenance treatment asthma patient year age old women health endocrine fosamax alendronate sodium treatment prevention osteoporosis nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive ring follistim follitropin beta injection biological fertility treatment implanon etonogestrel implant single rod subdermal contraceptive implant cerazette desogestrel progestin oral contraceptive maxalt rizatriptan benzoate product acute treatment migraine arcoxia etoricoxib treatment arthritis pain avelox moxifloxacin company market united states broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infection hospital specialty immunology remicade simponi treatment inflammatory disease infectious disease isentress pegintron peginterferon alphab treatment chronic hepatitis cancidas caspofungin acetate antifungal product victrelis invanz ertapenem sodium treatment certain infection primaxin imipenem cilastatin sodium antibacterial product noxafil posaconazole prevention invasive fungal infection oncology temodar temozolomide market temodal outside united states treatment certain type brain tumor emend aprepitant prevention chemotherapyinduce postoperative nausea vomit cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution ophthalmic product bridion sugammadex sodium injection medication reversal certain muscle relaxant surgery integrilin eptifibatide treatment patient acute coronary syndrome diversify brand cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatment hypertension propecia finasteride product treatment male pattern hair loss zocor simvastatin statin modifying cholesterol claritin loratadine treatment seasonal outdoor allergy yearround indoor allergy remeron mirtazapine antidepressant proscar finasteride urology product treatment symptomatic benign prostate enlargement vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide hypertension andor heart failure product vaccine gardasil proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease table content animal health animal health segment discover develop manufacture market animal health product include vaccine principal market product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorder cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo bovine respiratory disease zilmax revalor improve production efficiency beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product nobivaccontinuum vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal activylscaliborexspot protect bite flea tick mosquitoe sandfly aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor antibiotic farmraised fish consumer care consumer care segment develop manufacture market overthecounter foot care sun care product principal product segment include overthecounter product claritin nondrowsy antihistamine miralax relief occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray zegerid otc treatment frequent heartburn foot care scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil discussion sale company product item management discussion analysis financial condition result operation product approval february fda approve zioptan tafluprost preservativefree prostaglandin analog ophthalmic solution reduce elevated intraocular pressure patient openangle glaucoma ocular hypertension merck exclusive commercial right tafluprost western europe exclude germany north america south america africa middle east india australia zioptan market saflutan certain market outside united states february fda approve janumet new treatment type diabete combine sitagliptin active component januvia extendedrelease metformin janumet provide convenient oncedaily treatment option health care provider patient need help control blood sugar addition february fda approve cosopt mercks preservativefree formulation cosopt ophthalmic solution indicate reduction elevate intraocular pressure appropriate patient openangle glaucoma ocular hypertension joint venture astrazeneca merck enter agreement astra astra develop market astra product united states merck astra form equally own joint venture develop market astra new prescription medicine united states include prilosec omeprazole class medication know proton pump inhibitor slow production acid cell stomach lining table content merck astra restructure joint venture merck acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement preferential return represent company share undistribute partnership azlp generally accept accounting principle gaap earning variable return relate companys limited partner interest conjunction restructuring discuss astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products april astrazeneca exercise asset option merck receive million astrazeneca represent net present value march project future pretax revenue receive merck nonppi products record reduction company investment azlp company recognize million defer income component income expense net addition merck grant astra option buy merck common stock interest kbi mercks interest nexium prilosec azlp exercisable june merck astrazeneca amend option agreement update agreement eliminate astrazenecas option acquire merck interest kbi provide astrazeneca new option acquire mercks interest kbi june result amend agreement merck continue record supply sale equity income partnership astrazeneca option purchase merck interest kbi base value merck interest nexium prilosec astrazenecas option exercisable march april astrazeneca choose exercise option closing date expect june amend agreement astrazeneca payment merck closing million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june exercise price include additional equal multiple time merck average annual profit allocation partnership year prior exercise company believe likely astrazeneca exercise option astrazeneca exercise option company long record equity income azlp supply sale azlp decline substantially sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution thenexiste european free trade association merck sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory license subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product outside united states japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition table content scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi follow receipt pricing reimbursement approval april merck reach agreement amend agreement govern distribution right remicade simponi term amend distribution agreement merck relinquish marketing right remicade simponi territory include canada central south america middle east africa asia pacific effective july merck retain exclusive marketing right europe russia turkey retain territory addition begin july profit derive merck exclusive distribution product retain territory equally divide merck receive onetime payment merck million april competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug consumer health care manufacturer company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor company consumer care operation face competition consumer health care business retailer carry private label brand companys competitive position affect factor include regulatory legislative issue scientific technological advance quality price company product promotional effort growth low cost private label brand health care environment global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient table content backdrop united states enact major health care reform legislation began implement insurance market reform advance continue implementation law expect expand access health care million americans end decade previously insurance coverage respect effect law pharmaceutical industry mandate medicaid rebate increase expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual health care reform fee total annual industry fee billion billion fee assess company proportion share sale certain government program medicare medicaid company record million million cost marketing administrative expense respectively annual health care reform fee company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country announce austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance additionally global economic downturn sovereign debt issue certain european country factor adversely affect foreign receivables certain european country company continue receive payment receivable condition result increase average length time take collect account receivable outstanding adversely affect cash flow government emerge market focus constrain health care cost enact price control relate measure aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market company focus share revenue emerge market increase country market subject condition affect company effort continue grow emerge market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure table content impact health care reform continue budget pressure government world predict time address cost containment pressure company engage public policy advocacy policymaker continue attempt demonstrate medicine provide value patient pay health care company seek work government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate government health care spending company encourage government increase investment order improve citizen access appropriate health care include medicine certain market outside united states implement health technology assessment cost management strategy require additional data review administrative process increase complexity cost obtain product reimbursement exert downward pressure reimbursement available obtain operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force government regulation pharmaceutical industry subject regulation regional country state local agency world governmental regulation legislation tend focus standard process determine drug safety effectiveness condition sale reimbursement especially relate pricing product particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care example company recognize price product differential pricing framework take consideration factor country level economic development public health need addition merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine building company effort merck undertake collaboration stakeholder improve access medicine enhance quality life people world table content example merck announce launch merck mother longterm effort global health partner create world woman die preventable complication pregnancy childbirth launch include year million initiative apply mercks scientific business expertise make prove solution widely available develop new technology improve public awareness policy effort private sector engagement reduce maternal mortality merck past provide fund merck foundation independent organization partner variety organization dedicate improve global health partnership african comprehensive hivaids partnership botswana collaboration government botswana renew support botswana response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include recently enact law regulation united states europe asia latin america increase enforcement activity united states develop market distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer companys overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term patent term restoration period patent product regulatory review fda table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include patent term restoration pediatric exclusivity major market product product year expiration propecia formulationuse asmanex use formulation avelox dulera useformulation combination integrilin compound useformulation nasonex useformulationformulation temodar emend follistim pegintron conjugate mature ifnalpha invanz compound composition zostavax use zetiavytorin nuvare delivery system noxafil rotateq intron recombivax method makingvector saphrissycrest useformulation pende patent term restoration januviajanumetjuvisyncjanumet compound salt zioptan pende patent term restoration isentress victrelis pende patent term restoration gardasil compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability agreement generic manufacturer enter market january given right enter july generic version propecia agreement generic manufacturer launch generic version avelox united states february agreement generic manufacturer grant right merck nasonex use patent united states addition recent court decision find propose generic product generic manufacturer infringe merck nasonex formulation patent generic manufacturer application approve fda enter market united states generic version nasonex decision appeal agreement generic manufacturer launch generic version temodar united states august agreement generic manufacturer launch generic version zetia united states december expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country patent provide market exclusivity avelox expire march agreement generic manufacturer launch generic version avelox united states february patent provide market exclusivity united states temodar expire february agreement generic manufacturer launch generic version temodar united states august company anticipate sales united states decline significantly patent expiry table content addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty company follow key patent protection drug candidate review united states fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration mkc ezetimibeatorvastatin sugammadex sodium injection suvorexant company follow key patent protection drug candidate phase iii development currently anticipate phase iii drug candidate year expiration inactivated varicella zoster virus vzv vaccine method use mka nomace use corifollitropin alfa injection formulation pediatric hexavalent combination vaccine method makingvectors preladenant ragweed grass pollen odanacatib vorapaxar vintafolide anacetrapib psoriasis composition mka actoxumabbezlotoxumab hpv vaccine valent diabete mellitus compound patent note subject future patent term restoration year month pediatric market exclusivity available depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide efficacious long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend year orphan drug indication year marketing approval biological product information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold table content research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion billion include restructuring cost year million million billion inprocess research development impairment charge respectively company maintain ongoing commitment research broad range therapeutic area clinical development support new product company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value approve medicine vaccine new indication new formulation important component company sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide small protein antibodie rnai merck move diversify portfolio biosimilar potential harness market opportunity present biological medicine patent expiry deliver high quality followon biologic product enhance access patient worldwide company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease insomnia neurodegenerative disease osteoporosis respiratory disease women health development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include nda drug bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic molecule believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase iiaiib trial design twostage trial design consist phase iia proofofconcept stage phase iib doseoptimization finding stage datum phase trial satisfactory company commence largescale phase iii trial confirm compound efficacy safety completion trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate table content safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase iii trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter state application approve present form describe deficiency fda identify company wish pursue application receive complete response letter resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member states research development update company currently candidate regulatory review united states internationally suvorexant investigational insomnia medicine new class medicine call orexin receptor antagonist use patient difficulty fall stay asleep review fda suvorexant evaluate control substance staff fda nda review approve fda suvorexant available schedule assessment determination complete drug enforcement administration routinely occur fda approval company submit new drug application suvorexant health authority japan continue plan seek approval suvorexant country world sugammadex sodium injection investigational agent reversal neuromuscular blockade induce rocuronium vecuronium neuromuscular block agent review fda neuromuscular blockade anesthesiology induce muscle relaxation surgery approve new class medicine united states know selective relaxant bind agent surgical set fda approve original nda sugammadex sodium injection request additional datum relate hypersensitivity allergic reaction coagulation bleed event merck submit request datum nda resubmission fda deem complete review company expect fdas review complete half sugammadex sodium injection approve launch country outside united states market bridion table content vintafolide investigational cancer candidate review ema exclusive license agreement endocyte merck responsible development worldwide commercialization vintafolide oncology ema accept maa filing vintafolide endocyte investigational companion diagnostic imaging agent etarfolatide target treatment patient folatereceptor positive platinumresistant ovarian cancer combination pegylate liposomal doxorubicin vintafolide etarfolatide grant orphan drug status vintafolide phase iii development united states mkc investigational combination ezetimibe atorvastatin treatment primary mixed hyperlipidemia review fda update nda mkc deem complete review fda merck submit additional data response fda complete response letter issue merck expect fdas review complete half merck continue forward plan filing ezetimibe atorvastatin combination tablet additional country world addition candidate regulatory review company drug candidate phase iii development target broad range disease company anticipate file nda bla applicable fda respect candidate ninevalent hpv vaccine development help protect certain hpvrelate disease incorporate antigen additional cancercause hpv type compare gardasil previously disclose patient phase iii eventdriven clinical study ongoing merck anticipate file bla fda corifollitropin alpha injection market elonva investigational fertility treatment control ovarian stimulation woman participate vitro fertilization intracytoplasmic sperm injection currently phase iii development united states merck continue anticipate file nda fda vorapaxar thrombin receptor antagonist develop prevention thrombosis clot formation reduction cardiovascular event vorapaxar evaluate major clinical outcome study different patient group tracer thrombin receptor antagonist clinical event reduction acute coronary syndrome clinical outcome trial patient acute coronary syndrome trap thrombin receptor antagonist secondary prevention atherothrombotic ischemic event secondary prevention study patient previous heart attack ischemic stroke document peripheral vascular disease march result trap study vorapaxar present american college cardiology annual scientific session publish concurrently online edition new england journal medicine study addition vorapaxar standard care aspirin thienopyridine result significantly great reduction risk composite cardiovascular death heart attack stroke urgent coronary revascularization significant increase bleed include intracranial hemorrhage patient take vorapaxar addition standard care risk intracranial hemorrhage low patient history stroke november researcher present result tracer outcome study american heart association scientific session result publish tracer achieve primary endpoint january merck external study investigator announce combined datum safety monitoring board dsmb clinical trial review available safety efficacy datum recommend patient tracer trial discontinue study drug investigator close study follow review clinical trial datum discussion external expert merck plan file application vorapaxar united states seek indication prevention cardiovascular event patient history heart attack history transient ischemic attack stroke investigational allergy immunotherapy sublingual tablet ait phase iii development grass pollen allergy company north american right ait dissolvable oral tablet design prevent allergy symptom induce protective immune response allergy treat underlying cause disease merck investigate ait treatment grass pollen allergic rhinoconjunctivitis child adult company submit bla fda table content ait ragweed allergy phase iii development north american market company anticipate file bla fda mka nomace market zoely investigational oral contraceptive use woman prevent pregnancy nomace combine oral contraceptive tablet contain unique monophasic combination hormone nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar naturally present women body november merck receive complete response letter fda nomace company conduct additional clinical study request fda plan update application future odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal woman osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis july merck announce update phase iii trial assess fracture risk reduction odanacatib independent datum monitor committee dmc study complete plan interim analysis efficacy recommend study close early robust efficacy favorable benefitrisk profile dmc note safety issue remain certain select area recommendation respect follow february merck announced recently receive review safety efficacy datum phase iii trial result review datum company conclude review additional datum previously plan ongoing extension study warrant filing application approval fda delay previously announce company conduct blinded extension trial approximately woman provide additional safety efficacy datum merck anticipate file application approval odanacatib additional data extension trial company continue believe odanacatib potential address unmet medical need patient osteoporosis preladenant selective adenosine receptor antagonist phase iii development treatment parkinson disease company anticipate file nda fda inactivated vzv vaccine development prevention herpe zoster company enrol phase iii trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy company anticipate file bla autologous hematopoietic cell transplant datum file second indication cancer patient later date investigational hexavalent pediatric combination vaccine contain component current vaccine design help protect potentially disease diphtheria tetanus whooping cough bordetella pertussis polio poliovirus type invasive disease cause haemophilus influenzae type hepatitis develop collaboration sanofipasteur company anticipate file bla fda vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis virus development japan company anticipate file new drug application japan investigational onceweekly dpp inhibitor development treatment type diabetes company anticipate file nda fda antiinterleukin monoclonal antibody candidate investigate treatment psoriasis company anticipate file bla fda mka actoxumabbezlotoxumab investigational candidate treatment clostridium difficile infection combination monoclonal antibody treat patient single infusion company anticipate file bla mka fda table content anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigate lipid management raise hdlc reduce ldlc base result phase iii define determine efficacy tolerability cetp inhibition anacetrapib safety study patient coronary heart disease coronary heart disease risk equivalent company initiate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease predict complete company continue anticipate file nda anacetrapib fda merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease december merck announce initiation phase iiiii clinical trial epoch design evaluate safety efficacy versus placebo patient mildtomoderate alzheimer disease ridaforolimus investigational oral mtor mammalian target rapamycin inhibitor development cancer indication june merck announce fda issue complete response letter nda ridaforolimus treatment metastatic soft tissue bone sarcoma complete response letter state fda approve application present form additional clinical trial need conduct assess safety efficacy november merck formally notify ema decision withdraw maa ridaforolimus accept ema company long plan pursue sarcoma indication united states continue support patient enrol ongoing clinical trial merck remain committed pursue ridaforolimus cancer indication exclusive license agreement ariad pharmaceuticals inc ariad merck responsible development worldwide commercialization ridaforolimus oncology december merck announce hpsthrive study mka tredaptive meet primary endpoint study add combination extendedrelease niacin laropiprant statin therapy significantly reduce risk combination coronary death nonfatal heart attack stroke revascularization compare statin therapy addition statistically significant increase incidence type non fatal adverse event group receive extendedrelease niacinlaropiprant compare statin therapy merck plan seek regulatory approval medicine united states january base understand preliminary datum hpsthrive study consultation regulatory authority merck begin take step suspend availability tredaptive approve use certain country outside united states clinical development program mkb combination product extendedrelease niacin laropiprant simvastatin previously discontinue merck announce return global marketing development right intravenous oral formulation vernakalant treatment atrial fibrillation cardiome pharma corp business reason merck decide discontinue clinical development program mke combination product sitagliptin atorvastatin treatment type diabete business reason table content chart reflect company research pipeline february candidate show phase iii include specific product date candidate enter phase iii development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation candidate phase additional indication therapeutic area additional claim line extension formulation inline product show phase phase iii phase iii entry date review allergy allergy atherosclerosis immunotherapy grass pollen march mkc ezetimibeatorvastatin alzheimer disease ragweed september insomnia atherosclerosis suvorexant asthma anacetrapib neuromuscular blockade reversal clostridium difficile infection sugammadex sodium injection bacterial infection mka actoxumabbezlotoxumab november platinumresistant ovarian cancer contraception vintafolide cancer mka nomace june footnote dalotuzumab diabete mellitus north american rights september phase iiiii adaptive design fertility company submit bla dinaciclib corifollitropin alfa injection july await acceptance ridaforolimus hepatitis review fda cmv prophylaxis transplant patient vaniprevir june november merck receive letermovir herpes zoster complete response letter fda contraception medicate ius inactivated vzv vaccine december nomace mka conm trk generation ring hpv acc valent september anm scp een huu eec pen pdg iba cyn tan fud ture mka osteoporosis development japan mkb odanacatib september hepatitis parkinson disease preladenant july pediatric hexavalent combination vaccine hiv april platinumresistant ovarian cancer insomnia vintafolide april melanoma psoriasis december migraine thrombosis vorapaxar september overactive bladder pneumoconjugate vaccine rheumatoid arthritis employees december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group company commence action global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business design optimize cost structure combine company initial action expect result workforce reduction approximately primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility july company initiate action merger restructuring program company expect reduce workforce measure time merger additional company worldwide majority workforce reduction associate additional action relate manufacturing include table content animal health administrative headquarters organization inception merger restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position october merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy company worldwide inception restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million million million estimate million aggregate year amount consider potential recovery party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck expand operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time financial information geographic area company business discuss item financial statement supplementary datum available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section table content security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result singulair maxalt lose market exclusivity united states company experience significant decline sale product addition singulair maxalt lose market exclusivity company expect significant decline sale product market company depend patent provide exclusive marketing right product period time product patent company product recently expire united states country company face strong competition lower price generic drug loss patent protection company product typically lead rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect patent provide market exclusivity singulair company second large selling product globally sale billion expire august accordingly company experience significant rapid decline singulair sale decline fourth quarter million compare fourth quarter patent provide market exclusivity singulair expire number major european market february company expect significant rapid decline sale singulair market patent provide market exclusivity maxalt expire december patent provide market exclusivity maxalt expire number major european market august company anticipate sales united states approximately million european market decline significantly result patent expiry additional company product temodar propecia lose market exclusivity united states company anticipate sale decline significantly chart list patent protection company major market product set forth item business patent trademark license company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important table content company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate new drug application fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement discuss court decision find propose generic product generic manufacturer infringe company nasonex formulation patent generic manufacturer application approve fda enter market united states generic version nasonex adversely affect sale nasonex patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation recent court decision relate company patent potential legislation relate patent reform regulatory initiative result erosion intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result material noncash impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product januvia remicade zetia vytorin janumet isentress nasonex gardasil result company dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale certain product event result material noncash impairment charge company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year expect decline sale product singulair maxalt loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research develop new drug treat disease result high risk fund invest company research program generate financial return table content risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product singulair maxalt temodar propecia lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication increase uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection merger acquisition company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new table content product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postmarkete phase trial study decrease demand company product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity company face intense competition low costgeneric product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent table content protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation measure encourages use generic product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition competitor product addition factor certain circumstance lead non cash impairment charge company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect addition product measure fair value capitalize connection merger acquisition saphris merckschering plough partnership product vytorin zetia experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product company face pricing pressure respect product company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition company face risk litigation government pricing calculation outside united states numerous major market include pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future health care industry united states continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider congress state legislature major health care reform adopt law united states important market reform begin continue implementation new law expect expand access health care million americans end decade merck incur additional cost result law include increase medicaid rebate impact table content reduce revenue minimum rebate state participate medicaid program increase company brand prescription drug medicaid rebate extend medicaid manage care organization eligibility federal drug discount program extend rural referral center sole community hospital critical access hospital certain free stand cancer hospital certain additional children hospital addition law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million record merck reduction revenue respectively relate donut hole provision company require pay annual health care reform fee assess brand prescription drug manufacturer importer fee calculate base industry total sale brand prescription drug specify government program percentage manufacturer sale include determined tiere scale base manufacturers individual revenue manufacturers portion total annual fee base manufacturer proportion total includable sale prior year annual industry fee billion billion company record million million cost marketing administrative expense respectively annual health care reform fee company predict likelihood future change health care industry general pharmaceutical industry particular impact company result operation financial condition business current uncertainty global economic condition austerity measure take certain government negatively affect company operating result current uncertainty global economic condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial position prospect global effort health care cost containment continue exert pressure product pricing market access worldwide international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action austerity measure continue negatively affect revenue performance company continue monitor credit economic condition greece spain italy portugal member economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding country impact likelihood collect outstanding account receivable december company account receivable greece italy spain portugal total approximately billion hospital public sector receivables approximately million aggregate approximately relate greece italy spain portugal respectively december company total account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables condition europe worsen country euro zone exit euro zone reintroduce legacy currency result economic currency impact affect market globally material adverse effect company result table content company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease company experience difficulty delay manufacture certain product previously disclose merck past experienced difficulty manufacture certain vaccine product similarly company past experienced difficulty manufacture certain animal health product currently experience difficulty manufacture certain women health product company work manufacturing issue assurance issue finally resolve addition difficulty company experience currently company experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale company face significant litigation relate vioxx september merck voluntarily withdraw vioxx arthritis acute pain medication market worldwide merck settle major portion product liability litigation company face material litigation arise voluntary withdrawal vioxx addition vioxx product liability lawsuit lawsuit certain state participate previouslydisclose settlement purport class action individual lawsuit bring merck current officer director merck allege merck false misleading statement vioxx violation federal security law state law suit refer vioxx security lawsuit vioxx security lawsuit transfer judicial panel multidistrict litigation jpml district court district new jersey district judge stanley chesler inclusion nationwide mdl shareholder mdl consolidated purpose merck name defendant action country outside united states suit refer vioxx international lawsuit table content vioxx litigation discuss fully item financial statement supplementary datum note contingency environmental liability company believe meritorious defense vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively vioxx lawsuit vigorously defend company insurance coverage respect vioxx lawsuit adequate cover defense cost loss company currently able estimate additional amount require pay connection vioxx lawsuit proceeding expect continue year company predict course proceeding view inherent difficulty predict outcome litigation particularly claimant claimant seek unspecified damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx lawsuit company establish material reserve potential liability relate remain vioxx lawsuit establish reserve relate settlement canadian vioxx litigation respect certain vioxx product liability lawsuit include previouslydisclose settlement relate lawsuit bring class missouri plaintiffs discuss item financial statement supplementary datum note contingency environmental liability series unfavorable outcome vioxx lawsuit result payment substantial damage material adverse effect company business cash flow result operation financial position prospect issue concern vytorin enhance clinical trial adverse effect sale vytorin zetia united states result improveit trial material adverse effect sale company sell vytorin zetia previously disclose january company announce result enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin vytorin significantly lower ldl bad cholesterol simvastatin significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient present acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease improveit trial schedule completion improveit trial blind interim efficacy analysis conduct dsmb trial approximately endpoint accrue respectively case dsmb recommend continue trial change design time second interim efficacy analysis dsmb state plan review datum approximately month review schedule march point month additional datum adjudicate base result review trial halt concern relate vytorin material adverse effect sale vytorin zetia issue concern enhance clinical trial adverse effect sale vytorin zetia continue adverse effect sale result improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin sale zetia vytorin materially adversely affect sale product materially adversely affect company business cash flow result operation financial position prospect materially adversely affect company require record material noncash impairment charge table content company able realize expect benefit investment emerge market company take step increase presence emerge market guarantee company effort expand sale emerge market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect instance february venezuelan government devalue currency result devaluation company recognize loss exchange reason sale emerge market carry significant risk failure continue expand company business emerge market material adverse effect business financial condition result company operation company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue february president obamas administration repropose significant change international tax law include change tax company excess return attributable certain offshore intangible asset limit tax deduction expense relate unrepatriated foreignsource income modify foreign tax credit rule potentially significant change international law include territorial tax system set congressional committee company determine proposal enact law change proposal prior enact law change international tax law enact significant impact financial result company addition company affect change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction table content pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure size complexity company computer system make potentially vulnerable service interruption malicious intrusion random attack addition datum privacy security breach employee pose risk datum include intellectual property personal information expose unauthorized individual public assurance company effort protect datum system prevent service interruption loss critical sensitive information result financial legal business reputational harm company negative event animal health industry negative impact future result operation future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation table content multiple jurisdiction united states result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval require release manufacture commercial lot manufacture biologic especially large quantity complex require use innovative technology handle living micro organism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company required provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include table content know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic product company product singulair maxalt lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant litigation relate vioxx fosamax legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continues evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment table content item property companys corporate headquarters currently locate whitehouse station new jersey company announce intends headquarters summit new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd whitehouse station company vaccine business conduct divisional headquarters locate west point pennsylvania mercks animal health global headquarters function locate summit new jersey principal research facility locate rahway kenilworth summit new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facility outside locate netherlands switzerland china company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure billion billion billion united states amount billion billion million abroad expenditure amount million million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference note contingency environmental liability include item financial statement supplementary datum item safety disclosure applicable executive officer registrant age february time merger november certain executive officer assume position newly merge company note kenneth frazi age december chairman president chief executive officer merck inc january president chief executive officer merck inc president merck inc responsible company large worldwide division global human health merck manufacturing division merck research laboratory november executive vice president president global human health merck inc responsible company market sale organization worldwide include global pharmaceutical vaccine franchise august executive vice president president global human health merck inc responsible company market sale organization worldwide include global pharmaceutical vaccine franchise table content adele ambrose age november senior vice president chief communication officer merck inc responsible global communication organization december vice president chief communication officer merck inc responsible global communication organization john canan age november senior vice president financeglobal controller merck inc responsible company global controller organization include accounting control external reporting financial standard policy january senior vice president controller merck inc responsible corporate controller group willie deese age november executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function january executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function richard deluca age september executive vice president president merck animal health merck inc responsible merck animal health organization prior september deluca chief financial officer becton dickinson bioscience medical technology company president wyeths fort dodge animal health division serve chief operating officer fort dodge executive vice president chief financial officer cuong viet age october executive vice president chief strategy officer merck inc responsible leading formulation execution company long term strategic plan prior october senior vice president corporate strategy business development connectivity global company design manufacture market product customer variety industry senior vice president chief strategy officer lenovo personal technology company clark golestani age december executive vice president chief information officer merck inc responsible mercks global information technology august vice president merck research laboratorie information technology merck inc responsible global mercks research development division include basic research preclinical clinical regulatory november vice president corporate information technology merck inc responsible global support finance human resource procurement legal public affair site service real estate share business service operation table content mirian graddickweir age november executive vice president human resource merck inc responsible global human resource organization january executive vice president human resource merck inc responsible global human resource organization bridgette heller age march executive vice president president merck consumer care merck inc responsible merck consumer care organization prior march heller president johnson johnsons global baby business unit michael holston age june executive vice president chief ethic compliance officer merck inc responsible company compliance function include global safety environment system assurance ethic privacy prior june holston executive vice president general counsel board secretary hewlettpackard company technology company oversaw legal compliance government affair privacy ethic operation peter kellogg age november executive vice president chief financial officer merck inc responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship august executive vice president chief financial officer merck inc responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship peter kim age november executive vice president president merck research laboratories merck inc responsible company research development effort worldwide january executive vice president president merck research laboratories merck inc responsible company research development effort worldwide bruce kuhlik age november executive vice president general counsel merck inc responsible legal communication public policy function january executive vice president general counsel merck inc responsible legal communication public policy function michael rosenblatt age december executive vice president chief medical officer merck inc company primary voice global medical community critical issue patient safety oversight company global center scientific affair prior december rosenblatt dean tufts university school medicine table content adam schechter age executive vice president president global human health merck inc responsible company pharmaceutical vaccine worldwide business november president global human health marketintegration leader merck inc commercial responsibility united states company portfolio prescription medicine leader integration effort merckscheringplough merger division function august president global pharmaceuticals global human health merck inc global responsibility company atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchise commercial responsibility united states company portfolio prescription medicine officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year common stock market price high low high low january approximately shareholder record table content equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualified plan msd employee saving security plan scheringplough employee saving plan weight number number average security remain security exercise available future issue price issuance equity exercise outstanding compensation plan outstanding option exclude option warrant warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck inc nonemployee directors stock option plan merck inc scheringplough stock incentive plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan share restrict stock unit performance share unit exclude accrue dividend merck inc scheringplough stock incentive plan exclude share phantom stock defer msd employee deferral program share phantom stock defer msd director deferral program table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp performance graph reflect scheringplough stock performance december close merger merck stock performance november december assume cash component merger consideration reinveste merck stock closing price november compound annual growth rate october wyeth pfizer inc complete previously announce merger pfizerwyeth merger wyeth whollyowne subsidiary pfizer inc discuss november merck scheringplough complete merger pfizerwyeth merger transaction merck subsequently rename merck sharp dohme corp msd whollyowne subsidiary scheringplough subsequently rename merck inc result transaction wyeth msd long exist publicly trade entity cease trade common stock close business respective merger date wyeth msd permanently remove peer group index table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck inc subsidiarie million share amount result year sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder cash dividend declare cash dividend pay common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include amortization purchase accounting adjustment net charge record connection litigation settlement inprocess research development impairment charge reflect research development expense impact restructuring action favorable impact certain tax item amount include amortization purchase accounting adjustment inprocess research development impairment charge reflect research development expense impact restructuring action arbitration settlement charge favorable impact certain tax item include net favorable impact approximately million relate settlement federal income tax audit amount include amortization purchase accounting adjustment inprocess research development impairment charge billion reflect research development expense impact restructuring action reserve relate vioxx litigation gain recognize astrazeneca lps exercise option acquire certain asset company favorable impact certain tax item amount include impact merger scheringplough corporation november include recognition gain represent fair value stepup merck previously hold interest merckscheringplough partnership result obtain control interest amortization purchase accounting adjustment record postmerger period include gain sale merck interest merial limited favorable impact certain tax item impact restructuring action amount include gain distribution astrazeneca gain relate sale remain worldwide right aggrastat favorable impact certain tax item impact restructure action expense contribution merck foundation reflect dividend pay common shareholder merck addition approximately million dividend pay subsequent merger scheringplough million pay prior merger relate common stock prefer stock dividend declare scheringplough table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel overview merck continue execute strategic priority despite face business challenge include august patent expiration singulair medicine indicate chronic treatment asthma relief symptom allergic rhinitis worldwide sale billion decline compare include unfavorable effect foreign exchange exclude impact foreign exchange sale increase reflect growth key product key geographic region offset impact singulair patent expiration company reduce operating expense efficiently manage cost target reduction addition company generate new clinical datum advance certain key research development pipeline program company fourpart growth strategy focus execute core business include large market core brand new launch brand research development effort target therapeutic area great future patient demand scientific opportunity expand geographically highgrowth market extend complementary business consumer care animal health effectively manage cost continue invest future growth begin company sale performance large market despite adverse effect singulair patent expiry cause significant rapid decline singulair sale sale united states relatively flat compare prior year reflect strong growth key brand include januvia janumet treatment type diabete zostavax vaccine help prevent shingles herpe zoster gardasil vaccine help prevent certain disease cause type human papillomavirus hpv victrelis treatment chronic hepatitis isentress antiretroviral therapy use combination therapy treatment hiv infection turn europe canada company continue experience positive volume growth trend key brand include victrelis januvia janumet simponi treatment inflammatory disease growth partially offset increase generic erosion price decline stem economic issue relate fiscal austerity measure region respect research development effort company continue advancement drug candidate pipeline company currently candidate review food drug administration fda suvorexant investigational treatment insomnia sugammadex sodium injection medication reversal certain muscle relaxant surgery mkc investigational combination ezetimibe atorvastatin treatment primary mixed hyperlipidemia vintafolide investigational cancer candidate review european union table content addition company currently candidate phase iii development anticipate file new drug application nda biologics license application bla applicable fda respect candidate december company announce hpsthrive heart protection study treatment hdl reduce incidence vascular event study tredaptive extendedrelease niacinlaropiprant meet primary endpoint result company plan seek regulatory approval medicine united states january merck begin take step suspend availability tredaptive outside united states february company announce recently receive review safety efficacy datum phase iii study involve odanacatib company investigational treatment osteoporosis postmenopausal woman result review datum company conclude review additional datum previously plan ongoing extension study warrant filing application approval fda delay previously announce company conduct blinded extension trial approximately woman provide additional safety efficacy datum merck anticipate file application approval odanacatib additional data extension trial company continue believe odanacatib potential address unmet medical need patient osteoporosis merck continue pursue opportunity establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound technology platform potential drive near longterm growth company complete variety transaction span different therapeutic area clinical stage include licensing agreement endocyte inc endocyte vintafolide investigational cancer candidate aicuris portfolio investigational medicine target human cytomegalovirus include letermovir consistent second element company strategy expand geographically highgrowth market japan key emerge market company continue invest market emerge market sale grow include unfavorable impact foreign exchange despite loss sale remicade simponi treatment inflammatory disease market relinquish johnson johnson arbitration settlement agreement discuss china continue important growth driver sale exceed billion represent growth prior year include favorable effect foreign exchange growth japan temper generic competition biennial price cut early year merck enter transaction design strengthen presence emerge market long term company joint venture simcere pharmaceutical group china begin preliminary operation late component merck strategy relate complementary business consumer care animal health merck animal health business continue solid contributor revenue growth include unfavorable effect foreign exchange reflect growth cattle poultry companion animal swine product line sale consumer care product grow include unfavorable effect foreign exchange lead scholl franchise high sale coppertone miralax claritin note element company strategy tightly manage cost invest growth consistent effort merck remain committed drive continuous productivity improvement enterprise continue realize cost saving area company saving result action include merger restructuring program discuss previously announce ongoing cost reduction activity nonrestructuringrelate activity end company achieve project billion annual net cost saving activity merger scheringplough corporation scheringplough merger global restructuring program initiate conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company workforce reduction associate plan relate elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company record total pretax restructuring cost million billion billion table content relate program cost associate company restructure action include material production cost market administrative expense research development expense restructure cost restructuring action merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate subsequent merger company rationalize number manufacture site worldwide remain action program result additional manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion billion company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect merger restructure program yield annual saving end approximately billion billion annual saving completion program approximately billion billion november mercks board director raise company quarterly dividend share share february merck reach agreement principle plaintiff resolve federal security classaction lawsuit pende district court district new jersey merck scheringplough certain current officer director enhance litigation propose agreement merck pay million resolve security class action merck defendant million resolve security class action scheringplough defendant connection settlement merck record pretax aftertax charge million reflect million anticipate insurance recovery earning common share assume dilution attributable common shareholder eps reflect net unfavorable impact result acquisitionrelate cost restructure cost charge relate enhance litigation note nongaap eps exclude item nongaap income nongaap eps competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug consumer health care manufacturer company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth company product therapeutic category table content highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor company consumer care operation face competition consumer health care business retailer carry private label brand companys competitive position affect factor include regulatory legislative issue scientific technological advance quality price company product promotional effort growth low cost private label brand health care environment global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation began implement insurance market reform advance continue implementation law expect expand access health care million americans end decade previously insurance coverage respect effect law pharmaceutical industry mandate medicaid rebate increase expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual health care reform fee total annual industry fee billion billion fee assess company proportion share sale certain government program medicare medicaid company record million million cost marketing administrative expense respectively annual health care reform fee company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country announce austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance table content additionally global economic downturn sovereign debt issue certain european country factor adversely affect foreign receivables certain european country company continue receive payment receivable condition result increase average length time take collect account receivable outstanding adversely affect cash flow government emerge market focus constrain health care cost enact price control relate measure aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market company focus share revenue emerge market increase country market subject condition affect company effort continue grow emerge market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure impact health care reform continue budget pressure government world predict time address cost containment pressure company engage public policy advocacy policymaker continue attempt demonstrate medicine provide value patient pay health care company seek work government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate government health care spending company encourage government increase investment order improve citizen access appropriate health care include medicine certain market outside united states implement health technology assessment cost management strategy require additional data review administrative process increase complexity cost obtain product reimbursement exert downward pressure reimbursement available obtain operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force government regulation pharmaceutical industry subject regulation regional country state local agency world governmental regulation legislation tend focus standard process determine drug safety effectiveness condition sale reimbursement especially relate pricing product particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business table content company believe continue able conduct operation include launch new drug regulatory environment access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care example company recognize price product differential pricing framework take consideration factor country level economic development public health need addition merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine building company effort merck undertake collaboration stakeholder improve access medicine enhance quality life people world example merck announce launch merck mother longterm effort global health partner create world woman die preventable complication pregnancy childbirth launch include year million initiative apply mercks scientific business expertise make prove solution widely available develop new technology improve public awareness policy effort private sector engagement reduce maternal mortality merck past provide fund merck foundation independent organization partner variety organization dedicate improve global health partnership african comprehensive hivaids partnership botswana collaboration government botswana renew support botswana response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include recently enact law regulation united states europe asia latin america increase enforcement activity united states develop market operating result sale worldwide sale total billion decline compare billion foreign exchange unfavorably affect global sale performance sale decrease drive primarily singulair lose market exclusivity united states august result significant rapid decline singulair sale sale decline drive low sale remicade treatment inflammatory disease largely result arbitration settlement agreement discuss addition low sale cozaar hyzaar treatments hypertension clarinex nonsedate antihistamine fosamax treatment osteoporosis vytorin cholesterol modify medicine primaxin antibacterial product avelox broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infection low revenue company relationship astrazeneca azlp contribute sale decline decline largely offset high sale januvia gardasil victrelis zostavax janumet isentress zetia cholesterol modify medicine dulera combination medicine treatment asthma high sale company animal health consumer care product sale united states billion decline compare billion sale decrease drive low sale singulair vytorin avelox cozaar hyzaar low revenue company relationship azlp decline largely offset high sale table content januvia zostavax gardasil victrelis janumet isentress pneumovax vaccine help prevent pneumococcal disease zetia dulera high sale animal health consumer care product international sale billion decline compare billion foreign exchange unfavorably affect international sale performance decline europe canada partially offset growth japan certain emerge market particularly china low sale remicade lead decline low sale cozaar hyzaar singulair fosamax clarinex partially offset growth januvia victrelis gardasil janumet international sale represent total sale global effort health care cost containment continue exert pressure product pricing market access worldwide international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action austerity measure continue negatively affect revenue performance worldwide sale total billion increase compare billion foreign exchange favorably affect global sale performance revenue increase drive largely growth januvia janumet singulair isentress gardasil simponi rotateq vaccine help protect rotavirus gastroenteritis infant child zetia pneumovax bridion reversal certain muscle relaxant surgery addition revenue benefit high sale company animal health product launch victrelis increase partially offset low sale cozaar hyzaar vytorin temodar treatment certain type brain tumor proquad pediatric combination vaccine help protect measle mump rubella varicella varivax vaccine help prevent chickenpox varicella revenue negatively affect low sale caelyx subutex suboxone company long marketing right product addition ongoing implementation certain provision health care reform legislation result increase medicaid rebate impact reduce revenue compare table content sale company product follow million primary care women health cardiovascular zetia vytorin diabetes obesity januvia janumet respiratory singulair nasonex clarinex dulera asmanex womens health endocrine fosamax nuvare follistim implanon cerazette maxalt arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress pegintron cancida victrelis invanz primaxin noxafil oncology temodar emend cosopttrusopt bridion integrilin diversify brand cozaarhyzaar propecia zocor claritin remeron proscar vasotecvaseretic vaccine gardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health consumer care alliance alliance segment include revenue company relationship azlp revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content pharmaceutical segment primary care women health cardiovascular worldwide sale zetia market ezetrol outside united states cholesterol absorption inhibitor increase billion include unfavorable effect foreign exchange sale increase reflect positive performance united states price volume growth japan partially offset volume decline united states sales zetia increase billion include favorable effect foreign exchange increase reflect high sale international market particularly japan partially offset volume decline united states global sale vytorin market outside united states inegy combination product contain active ingredient zetia zocor decline billion include unfavorable effect foreign exchange sale decline reflect volume decline united states partially offset pricing united states volume growth certain international market worldwide sale vytorin decline billion reflect volume decline united states partially offset increase international market march datum safety monitoring board dsmb improveit trial large cardiovascular outcome study evaluate ezetimibesimvastatin simvastatin patient present acute coronary syndrome complete second prespecified interim efficacy analysis study dsmb conduct plan interim efficacy analysis trial reach approximately target clinical endpoint call study design dsmb recommend study continue change design state planned review datum approximately month review schedule march point month additional datum adjudicate merck remain blind improveit safety efficacy datum improveit patient eventdriven trial base current rate event report company anticipate target clinical endpoint study completion reach december merck announce hpsthrive study tredaptive meet primary endpoint research development subsequently base understand preliminary datum hpsthrive study consultation regulatory authority merck begin take step suspend availability tredaptive approve use certain country outside united states company recognize approximately million cost associate suspend availability tredaptive sale tredaptive million diabete obesity global sale januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabete rise billion grow billion reflect volume growth united states international market particularly japan foreign exchange unfavorably affect sale performance favorably affect sale performance worldwide sale janumet merck oral antihyperglycemic agent combine sitagliptin januvia metformin single tablet target key defect type diabete billion increase compare reflect volume growth united states emerge market europe global sale janumet billion compare million reflect growth internationally ongoing launch certain market growth united states foreign exchange unfavorably affect sale performance favorably affect sale performance february fda approve janumet new treatment type diabetes combine sitagliptin extendedrelease metformin janumet provide convenient oncedaily treatment option health care provider patient need help control blood sugar previously disclose february fda send warning letter company relate januvia janumet state company fulfill postmarkete requirement month pancreatic safety study diabetic rodent model treat sitagliptin company complete study table content submit study report fda december fda recently review submission conclude postmarkete requirement fulfil respiratory worldwide sale singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis decline billion drive primarily low sale united states revenue decline europe canada latin america contribute singulair sale decline patent provide market exclusivity singulair expire august company experience significant rapid decline singulair sale sale singulair decline fourth quarter million sale singulair decrease billion year drive low sale patent expiry august addition patent provide market exclusivity singulair expire number major european market february company expect significant rapid reduction sale singulair market patent provide market exclusivity singulair japan expire sale singulair million europe million japan global sale singulair grow billion include favorable impact foreign exchange drive primarily favorable pricing united states volume growth japan emerge market global sale nasonex inhale nasal corticosteroid treatment nasal allergy symptom decline billion include unfavorable impact foreign exchange sale performance reflect price decline europe low volumes united states largely offset high price united states apotex inc apotex corp collectively apotex file abbreviate new drug application fda seek approval sell generic version nasonex june district court district new jersey rule company patent infringement suit apotex hold apotexs generic version nasonex infringe company formulation patent note consolidated financial statement company appeal district court decision generic version available significant loss nasonex sale occur company noncash impairment charge respect value nasonex intangible asset carrying value approximately billion december nasonex intangible asset determine impaired impairment charge material result unfavorable district court decision company evaluate nasonex intangible asset impairment conclude impair sale nasonex million worldwide sale nasonex increase billion include favorable effect foreign exchange sale increase drive largely volume growth japan latin america partially offset volume decline united states global sale clarinex market aerius country outside united states nonsedate antihistamine decline million drive low volume europe united states result generic competition previously disclose virtue litigation settlement certain generic manufacturer give right enter market generic version launch company anticipate sale clarinex continue decline worldwide sale clarinex million compare million global sale dulera inhalation aerosol combination medicine treatment asthma million compare million reflect volume growth united states dulera inhalation aerosol approve fda june january merck receive complete response letter fda company supplemental new drug application dulera treatment chronic obstructive pulmonary disease company planning conduct additional clinical study update application future women health endocrine worldwide sale fosamax fosamax plus market fosavance fosamac japan treatment case fosamax prevention osteoporosis decline million decrease million medicine lose market exclusivity united states major european market decline japan emerge market contribute sale decrease company expect decline fosamax product franchise continue table content worldwide sale nuvare vaginal contraceptive product million comparable sale foreign exchange unfavorably affect sale performance exclude unfavorable impact foreign exchange sale performance reflect volume growth emerge market positive performance europe global sale nuvare grow million include beneficial effect foreign exchange drive positive performance united states internationally global sale follistim market country outside united states puregon biological fertility treatment decline million include unfavorable effect foreign exchange drive largely decline europe result supply issue pricing sale follistim million compare million reflect growth emerge market offset decline europe primarily supply constraint puregon lose market exclusivity august company currently experience difficulty manufacture certain women health product company work resolve issue material company result operation global sale maxalt product acute treatment migraine million comparable sale sale performance reflect high sale united states drive favorable pricing offset volume decline europe canada generic erosion sale maxalt increase million reflect high inventory level favorable pricing united states patent provide market exclusivity maxalt expire december company experience decline maxalt sale expect decline continue addition patent provide market exclusivity maxalt expire number major european market august company anticipate sale european market decline significantly patent expiry sale maxalt million united states million europe sale avelox broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infection market company united states decline million primarily competitor product available generic form sale avelox grow million patent provide market exclusivity avelox expire march agreement generic manufacturer launch generic version avelox february product include primary care women health include asmanex twisthaler inhale corticosteroid asthma implanon singlerod subdermal contraceptive implant cerazette progestin oral contraceptive arcoxia treatment arthritis pain hospital specialty immunology sale remicade treatment inflammatory disease billion decline compare billion decline compare foreign exchange unfavorably affect global sale performance favorably affect sale performance prior july remicade market company outside united states japan certain asian market result agreement reach april amend agreement govern distribution right remicade simponi effective july merck relinquish marketing right product certain territory include canada central south america middle east africa asia pacific merck retain exclusive marketing right europe russia turkey retain territory retain territory remicade sale decline reflect unfavorable effect foreign exchange volume growth europe sale remicade retain territory grow reflect favorable impact foreign exchange simponi oncemonthly subcutaneous treatment certain inflammatory disease approve european commission october sales simponi million million million revenue increase drive growth retain territory ongoing launch july submission european medicine agency ema request approval simponi treatment adult patient moderately severely active ulcerative colitis inadequate response conventional therapy table content infectious disease worldwide sale isentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection grow billion drive primarily volume growth united states latin america asia pacific region global sale isentress rise billion reflect volume growth united states internationally partially offset unfavorable pricing european market foreign exchange unfavorably affect global sale performance favorably affect sale performance worldwide sale pegintron treatment chronic hepatitis decline million include unfavorable effect foreign exchange exclude unfavorable impact foreign exchange sale performance reflect volume growth favorable pricing united states volume growth certain emerge market sale pegintron decline million include favorable effect foreign exchange reflect competitive pressure global sale cancidas antifungal product decline million include unfavorable effect foreign exchange exclude unfavorable impact foreign exchange sale performance reflect growth emerge market sale cancida grow million include favorable effect foreign exchange reflect high sale europe canada partially offset decline united states global sale victrelis company innovative oral medicine treatment chronic hepatitis million compare million drive postlaunch growth united states internationally particularly europe victrelis approve fda july victrelis approve country launch market sale primaxin antibacterial product decline million decrease million patent primaxin expire worldwide multiple generic launch oncology sale temodar market temodal outside united states treatment certain type brain tumor decline million include unfavorable effect foreign exchange sale decline europe generic competition offset price increase united states sale temodar decrease million include favorable effect foreign exchange primarily reflect generic competition europe temodar lose patent exclusivity previously disclose agreement generic manufacturer launch generic version temodar united states august accordingly company anticipate sale temodar million decline significantly patent exclusivity period expire february global sales emend prevention chemotherapyinduce postoperative nausea vomit increase million include unfavorable effect foreign exchange sale increase reflect volume growth united states japan sale emend increase million primarily reflect growth international market worldwide sale ophthalmic product cosopt trusopt decline million include unfavorable effect foreign exchange sale decline primarily reflect low sale europe generic erosion price reduction mitigate high cosopt sale japan sale cosopt trusopt decline million include favorable impact foreign exchange reflect unfavorable pricing volume decline europe partially offset high cosopt sale japan patent provide market exclusivity cosopt trusopt expire trusopt lose market exclusivity number major european market patent cosopt expire number major european market march company expect sale market decline significantly bridion sugammadex sodium injection reversal certain muscle relaxant surgery approve launch country outside united states sale bridion million million million sugammadex sodium injection currently review fda table content fda approve saphris asenapine antipsychotic indicate treatment schizophrenia bipolar disorder adult asenapine sell brand sycrest receive marketing approval treatment bipolar disorder adult merck lundbeck lundbeck announce worldwide commercialization agreement sycr sublingual tablet term agreement lundbeck pay fee make product supply payment exchange exclusive commercial right sycr market outside united states china japan merck sales saphris million million merck continue focus build maintain brand awareness saphris united states efforts united states lundbeck ongoing launch product successful company noncash impairment charge respect value saphrissycr intangible asset carrying value approximately million december saphrissycrest intangible asset determine impaired impairment charge material product contain hospital specialty include invanz treatment certain infection noxafil prevention certain invasive fungal infection integrilin treatment patient acute coronary syndrome sell company united states canada diversify brand mercks diversify brand include human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension decline billion decrease billion patent provide market exclusivity cozaar hyzaar united states number major international market expire accordingly company experience significant decline cozaar hyzaar sale company expect decline continue product contain diversified brand include propecia product treatment male pattern hair loss zocor statin modify cholesterol prescription claritin treatment seasonal outdoor allergy yearround indoor allergy remeron antidepressant proscar urology product treatment symptomatic benign prostate enlargement vasotec vaseretic hypertension andor heart failure product formulationuse patent provide market exclusivity propecia expire october previously disclose agreement generic manufacturer enter market january give right enter july accordingly company anticipate sale propecia million decline significantly vaccine follow discussion vaccine include sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate select joint venture affiliate information supply sale spmsd include worldwide sale gardasil record merck grow billion drive primarily growth united states reflect continued uptake male approximately million government purchase center disease control prevention cdc pediatric vaccine stockpile growth emerge market particularly latin america asia pacific region japan sales gardasil rise billion drive great uptake male united states high sale conjunction launch japan growth emerge market partially offset low government order canada gardasil worlds topselle hpv vaccine indicate girl woman year age prevention cervical vulvar vaginal anal cancer cause hpv type certain precancerous dysplastic lesion cause hpv type genital wart cause hpv type gardasil approve united states use boy man year age prevention anal cancer cause hpv type anal dysplasia precancerous lesion cause hpv table content type genital wart cause hpv type company party certain thirdparty license agreement respect gardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasil sale vary country include material production cost recent year company experience difficulty produce varicella zoster virus vzvcontaine vaccine difficulty result supply constraint proquad varivax zostavax company resolve supply constraint united states anticipate limited launch international market zostavax note proquad pediatric combination vaccine help protect measle mump rubella varicella vzvcontaining vaccine available united states order october merck sale proquad million million million sale year affect supply constraint merck sale varivax vaccine help prevent chickenpox varicella million million million sale reflect million government purchase cdcs pediatric vaccine stockpile merck sale mmr vaccine help protect measle mump rubella million million million sale growth drive primarily high volume united states sale varivax mmr affect proquad supply constraint discuss merck sale zostavax vaccine help prevent shingles herpe zoster adult year age old million million million sale performance reflect supply availability increase promotional effort united states sale affect supply issue company anticipate limited launch outside united states later merck sale rotateq vaccine help protect rotavirus gastroenteritis infant child decline million reflect favorable public sector inventory fluctuation partially offset volume growth emerge market japan mercks sale rotateq grow million reflect favorable public sector inventory fluctuation growth emerge market merck sale pneumovax vaccine help prevent pneumococcal disease grow million primarily growth united states result price increase high volume partially offset decline japan sales pneumovax increase million positive performance united states favorable pricing growth japan merck adult formulation vaqta vaccine hepatitis experience supply issue available quarter segment animal health animal health include pharmaceutical vaccine product prevention treatment control disease major farm companion animal species animal health sale affect intense competition frequent introduction generic product global sale animal health product grow billion increase billion foreign exchange unfavorably affect global sale performance favorably affect global sale performance increase sale period drive positive performance cattle poultry companion animal swine product consumer care consumer care product include overthecounter foot care sun care product claritin nondrowsy antihistamine miralax relief occasional constipation scholl foot care product coppertone sun care product global sale consumer care product grow include unfavorable effect foreign exchange billion reflect high sale scholl coppertone miralax claritin partially offset low sale marvelon oral contraceptive overthe table content counter product china sale increase billion reflect strong performance coppertone offset decline scholl claritin consumer care product sale affect competition consumer spending pattern january fda approve oxytrol woman overthecounter treatment overactive bladder woman company anticipate available customer fall alliance alliance segment include result company relationship azlp revenue azlp primarily relate sale nexium prilosec million billion billion astrazeneca option buy merck interest subsidiary merck interest nexium prilosec exercisable company believe likely astrazeneca exercise option select joint venture affiliate information astrazeneca exercise option company long record equity income azlp supply sale azlp decline substantially cost expense million change change material production marketing administrative research development restructuring cost equity income affiliate income expense net include million million billion iprd impairment charge respectively material production material production cost billion billion billion cost include expense amortization intangible asset record connection merger acquisition total billion billion additionally expense include million billion respectively amortization purchase accounting adjustment scheringplough inventory recognize result merger cost include intangible asset impairment charge million company recognize additional noncash impairment charge future relate product intangible measure fair value capitalize connection merger acquisition charge material include material production cost associate restructuring activity amount million million million respectively include accelerate depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare amortization intangible asset purchase accounting adjustment inventory restructuring impairment charge note reduce gross margin percentage point percentage point percentage point exclude impact gross margin decline compare reflect significant decline singulair sale result loss market exclusivity partially offset improvement result change product mix company anticipate gross margin continue negatively affect singulair patent expiry occur august singulair patent expiry major european market occur february addition anticipate generic competition united states maxalt propecia negatively impact gross margin gross margin improvement compare reflect change product mix manufacturing efficiency benefit foreign exchange table content market administrative marketing administrative expense decline billion favorable effect foreign exchange decline promotion cost low selling cost result restructuring activity market administrative expense grow billion unfavorable effect foreign exchange strategic investment emerge market market administrative expense include million million respectively expense annual health care reform fee require health care reform legislation expense include restructure cost million million million respectively relate primarily accelerate depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss expense include million million million acquisitionrelate cost respectively consist incremental thirdparty integration cost relate merger include cost relate legal entity system integration acquisition relate cost consist severance cost associate acquisition inspire pharmaceuticals inc company formal restructuring program research development research development expense billion billion billion research development expense comprise cost directly incur merck research laboratory mrl company research development division focus human health relate activity approximately billion billion include research development expense cost incur division support research development activity include depreciation production general administrative certain cost operate segment include pharmaceutical animal health consumer care segment aggregate billion billion billion respectively research development expense favorably affect cost saving result restructuring activity include research development expense upfront payment approximately million relate agreement endocyte aicuris research development research development expense include inprocess research development iprd impairment charge research developmentrelate restructuring charge company record million iprd impairment charge primarily pipeline program previously deprioritize subsequently deem alternative use period company record iprd impairment charge million primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value company record billion iprd impairment charge billion relate writedown intangible asset vorapaxar result development clinical program compound remain million iprd impairment charge record attributable compound abandon determine alternative use return respective licensor expect delay launch timing change cash flow assumption certain compound company recognize additional noncash impairment charge future cancellation delay pipeline program measure fair value capitalize connection merger acquisition charge material research development expense reflect million million million respectively accelerate depreciation asset abandonment cost associate restructuring activity company record adjustment accelerate depreciation cost include research development expense revise previously record amount certain facility sharebase compensation total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award table content recognize weight average period year segment report sharebased compensation cost unallocated expense restructure cost restructure cost million billion million respectively nearly cost record relate merger restructuring program restructuring cost record million relate merger restructuring program million relate global restructure program initiate restructuring program remain activity relate legacy scheringplough program include gain sale manufacturing facility separation cost million billion million respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate merck eliminate approximately position relate merger restructuring program relate restructuring program relate legacy scheringplough program approximately position relate merger restructuring program relate restructuring program relate legacy scheringplough program approximately position relate merger restructuring program relate restructuring program legacy schering plough program position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan costs contract termination shutdown cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production marketing administrative research development discuss equity income affiliate equity income affiliate reflect performance company joint venture equity method affiliate increase million grow million primarily high partnership return azlp company divest interest johnson johnsonmerck consumer pharmaceutical company jjmcp joint venture select joint venture affiliate information income expense net income expense net billion expense compare million expense drive primarily million net charge relate settlement enhance litigation note consolidated financial statement gain recognize million disposition company interest jjmcp joint venture note consolidated financial statement million sale certain manufacturing facility relate asset note consolidated financial statement partially offset million charge relate resolution arbitration proceeding involve company right market remicade simponi note consolidated financial statement high interest income income expense net billion expense reflect million charge settle certain litigation relate vioxx vioxx liability reserve charge relate settlement certain pende awp litigation million exchange loss venezuelan currency devaluation discuss partially offset million income recognize astrazenecas asset option exercise note consolidated financial statement million income recognize settlement certain dispute royalty february venezuelan government devalue currency bolvar fuerte vef dollar vef dollar company anticipate recognize loss exchange approximately million quarter result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation note exchange loss reflect loss relate venezuelan currency devaluation effective january venezuelan government devalue currency twotiere official exchange rate essential rate non essential rate december venezuelan government announce table content eliminate essential rate effective january result announcement company remeasure december monetary asset liabilitie new official rate segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment sale standard cost certain operating expense directly incur segment component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit charge relate settlement enhance litigation record arbitration settlement charge gain divestiture company interest jjmcp joint venture gain sale certain manufacturing facility relate asset record charge vioxx liability reserve income recognize astrazenecas asset option exercise recognize addition amortization purchase accounting adjustment acquisitionrelate cost intangible asset impairment charge restructure cost taxis pay joint venture level portion equity income exclude determination segment profit additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale pharmaceutical segment profit increase drive primarily low operating expense offset effect loss market exclusivity singulair pharmaceutical segment profit rose drive largely increase sale gross margin improvement discuss taxis income effective income tax rate reflect impact acquisitionrelate cost restructure cost partially offset beneficial impact foreign earning effective tax rate reflect favorable impact tax settlement canada revenue agency cra realization foreign tax credit impact favorable rule state tax matter addition effective tax rate reflect unfavorable impact net charge record connection settlement enhance litigation tax benefit record reflect impact tax credit expire december result legislation pass extend tax credit tax credit recognize entire tax credit recognize quarter effective tax rate reflect net favorable impact approximately million relate settlement merck federal income tax audit favorable impact certain foreign state tax rate change result net million reduction defer tax liability intangible establish purchase accounting unfavorable impact million charge relate resolution arbitration proceeding effective tax rate reflect impact vioxx liability reserve tax impact record million charge associate change tax law require taxation prescription drug subsidy company retiree health benefit plan enact quarter health care reform legislation impact astrazenecas asset option exercise unfavorable impact partially offset million tax benefit change foreign entitys tax rate result reduction defer tax liability product intangible record conjunction merger favorable impact foreign earning dividend companys foreign subsidiary table content net income earning common share net income attributable merck inc billion billion million eps decrease net income ep compare primarily net charge record connection settlement enhance litigation effect loss market exclusivity singulair favorable impact tax item partially offset low marketing administrative expense low restructuring cost low intangible asset impairment charge arbitration settlement charge record increase net income ep compare primarily lower iprd impairment charge amortization inventory stepup low legal reserve favorable impact tax settlement partially offset arbitration settlement charge record income recognize astrazenecas asset option exercise nongaap income nongaap ep nongaap income nongaap eps alternative view company performance management merck provide management believe information enhance investor understand company result nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consist acquisitionrelate cost restructure cost certain item exclude item significant component understand assess financial performance information nongaap income nongaap eps consider addition lieu net income ep prepared accordance generally accept accounting principle united states gaap additionally nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap income nongaap ep performance company measure basis performance metric senior management annual compensation derive nongaap income nongaap ep table content reconciliation gaap financial measure nongaap financial measure follow million share amount pretax income report gaap increase decrease exclude item acquisitionrelate cost restructure cost item net charge relate settlement enhance litigation arbitration settlement charge gain disposition interest jjmcp joint venture gain sale manufacturing facility relate asset vioxx liability reserve income recognize astrazenecas asset option exercise taxis income report gaap estimate tax benefit expense exclude item tax benefit settlement federal income tax audit tax benefit foreign state tax rate change tax charge relate health care reform legislation nongaap net income net income attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution represent difference calculate gaap ep calculate nongaap eps different calculate dividing impact exclude item weightedaverage share applicable year acquisitionrelate cost nongaap income nongaap eps exclude impact certain amount record connection merger acquisition amount include amortization intangible asset inventory stepup intangible asset impairment charge exclude incremental thirdparty integration cost associate merger cost relate legal entity system integration cost associate merger acquisition severance cost company formal restructuring program cost exclude management believe cost representative ongoing normal business activity restructure cost nongaap income nongaap eps exclude cost relate restructuring action include restructuring activity relate merger note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action company undertake table content restructuring different type cover period charge consider nonrecurre management exclude amount nongaap income nongaap eps believe helpful understanding performance continue business certain item nongaap income nongaap eps exclude certain item item represent substantive unusual item evaluate individual basis evaluation consider quantitative qualitative aspect unusual nature generally represent item result nature magnitude management anticipate occur company normal business regular basis certain item comprise net charge record connection settlement enhance litigation arbitration settlement charge gain disposition company interest jjmcp joint venture gain associate sale certain manufacturing facility relate asset charge establish vioxx liability reserve income recognize astrazenecas asset option exercise exclude nongaap income nongaap eps tax benefit settlement federal income tax audit favorable impact certain foreign state tax rate change result net reduction defer tax liability intangible establish purchase accounting tax charge relate health care reform legislation research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states internationally suvorexant investigational insomnia medicine new class medicine call orexin receptor antagonist use patient difficulty fall stay asleep review fda suvorexant evaluate control substance staff fda nda review approve fda suvorexant available schedule assessment determination complete drug enforcement administration routinely occur fda approval company submit new drug application suvorexant health authority japan continue plan seek approval suvorexant country world sugammadex sodium injection investigational agent reversal neuromuscular blockade induce rocuronium vecuronium neuromuscular block agent review fda neuromuscular blockade anesthesiology induce muscle relaxation surgery approve new class medicine united states know selective relaxant bind agent surgical set fda approve original nda sugammadex sodium injection request additional datum relate hypersensitivity allergic reaction coagulation bleed event merck submit request datum nda resubmission fda deem complete review company expect fdas review complete half sugammadex sodium injection approve launch country outside united states market bridion vintafolide investigational cancer candidate review ema exclusive license agreement endocyte merck responsible development worldwide commercialization vintafolide oncology ema accept marketing authorization application filing vintafolide endocyte investigational companion diagnostic imaging agent etarfolatide target treatment patient folatereceptor positive platinumresistant ovarian cancer combination pegylate liposomal doxorubicin vintafolide etarfolatide grant orphan drug status vintafolide phase iii development united states mkc investigational combination ezetimibe atorvastatin treatment primary mixed hyperlipidemia review fda update nda mkc deem complete table content review fda merck submit additional data response fda complete response letter issue merck expect fdas review complete half merck continue forward plan filing ezetimibe atorvastatin combination tablet additional country world addition candidate regulatory review company drug candidate phase iii development target broad range disease company anticipate file nda bla applicable fda respect candidate ninevalent hpv vaccine development help protect certain hpvrelate disease incorporate antigen additional cancercause hpv type compare gardasil previously disclose patient phase iii eventdriven clinical study ongoing merck anticipate file bla fda corifollitropin alpha injection market elonva investigational fertility treatment control ovarian stimulation woman participate vitro fertilization intracytoplasmic sperm injection currently phase iii development united states merck continue anticipate file nda fda vorapaxar thrombin receptor antagonist develop prevention thrombosis clot formation reduction cardiovascular event vorapaxar evaluate major clinical outcome study different patient group tracer thrombin receptor antagonist clinical event reduction acute coronary syndrome clinical outcome trial patient acute coronary syndrome trap thrombin receptor antagonist secondary prevention atherothrombotic ischemic event secondary prevention study patient previous heart attack ischemic stroke document peripheral vascular disease march result trap study vorapaxar present american college cardiology annual scientific session publish concurrently online edition new england journal medicine study addition vorapaxar standard care aspirin thienopyridine result significantly great reduction risk composite cardiovascular death heart attack stroke urgent coronary revascularization significant increase bleed include intracranial hemorrhage patient take vorapaxar addition standard care risk intracranial hemorrhage low patient history stroke november researcher present result tracer outcome study american heart association scientific session result publish tracer achieve primary endpoint january merck external study investigator announce combine dsmb clinical trial review available safety efficacy datum recommend patient tracer trial discontinue study drug investigator close study follow review clinical trial datum discussion external expert merck plan file application vorapaxar united states seek indication prevention cardiovascular event patient history heart attack history transient ischemic attack stroke investigational allergy immunotherapy sublingual tablet ait phase iii development grass pollen allergy company north american right ait dissolvable oral tablet design prevent allergy symptom induce protective immune response allergy treat underlying cause disease merck investigate ait treatment grass pollen allergic rhinoconjunctivitis child adult company submit bla fda ait ragweed allergy phase iii development north american market company anticipate file bla fda mka nomace market zoely investigational oral contraceptive use woman prevent pregnancy nomace combine oral contraceptive tablet contain unique monophasic combination hormone nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar naturally present women body november merck receive complete response letter fda nomace company conduct additional clinical study request fda plan update application future table content odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal woman osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis july merck announce update phase iii trial assess fracture risk reduction odanacatib independent datum monitor committee dmc study complete plan interim analysis efficacy recommend study close early robust efficacy favorable benefitrisk profile dmc note safety issue remain certain select area recommendation respect follow february merck announced recently receive review safety efficacy datum phase iii trial result review datum company conclude review additional datum previously plan ongoing extension study warrant filing application approval fda delay previously announce company conduct blinded extension trial approximately woman provide additional safety efficacy datum merck anticipate file application approval odanacatib additional data extension trial company continue believe odanacatib potential address unmet medical need patient osteoporosis preladenant selective adenosine receptor antagonist phase iii development treatment parkinson disease company anticipate file nda fda inactivated vzv vaccine development prevention herpe zoster company enrol phase iii trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy company anticipate file bla autologous hematopoietic cell transplant datum file second indication cancer patient later date investigational hexavalent pediatric combination vaccine contain component current vaccine design help protect potentially disease diphtheria tetanus whooping cough bordetella pertussis polio poliovirus type invasive disease cause haemophilus influenzae type hepatitis develop collaboration sanofipasteur company anticipate file bla fda vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis virus development japan company anticipates file new drug application japan investigational onceweekly dpp inhibitor development treatment type diabetes company anticipate file nda fda antiinterleukin monoclonal antibody candidate investigate treatment psoriasis company anticipate file bla fda mka actoxumabbezlotoxumab investigational candidate treatment clostridium difficile infection combination monoclonal antibody treat patient single infusion company anticipate file bla mka fda anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigate lipid management raise hdlc reduce ldlc base result phase iii define determine efficacy tolerability cetp inhibition anacetrapib safety study patient coronary heart disease coronary heart disease risk equivalent company initiate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease predict complete company continue anticipate file nda anacetrapib fda merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease december merck announce initiation phase iiiii clinical trial epoch design evaluate safety efficacy versus placebo patient mildtomoderate alzheimer disease table content ridaforolimus investigational oral mtor mammalian target rapamycin inhibitor development cancer indication june merck announce fda issue complete response letter nda ridaforolimus treatment metastatic soft tissue bone sarcoma complete response letter state fda approve application present form additional clinical trial need conduct assess safety efficacy november merck formally notify ema decision withdraw marketing authorization application ridaforolimus accept ema company long plan pursue sarcoma indication united states continue support patient enrol ongoing clinical trial merck remain committed pursue ridaforolimus cancer indication exclusive license agreement ariad pharmaceuticals inc ariad merck responsible development worldwide commercialization ridaforolimus oncology december merck announce hpsthrive study mka tredaptive meet primary endpoint study add combination extendedrelease niacin laropiprant statin therapy significantly reduce risk combination coronary death nonfatal heart attack stroke revascularization compare statin therapy addition statistically significant increase incidence type non fatal adverse event group receive extendedrelease niacinlaropiprant compare statin therapy merck plan seek regulatory approval medicine united states january base understand preliminary datum hpsthrive study consultation regulatory authority merck begin take step suspend availability tredaptive approve use certain country outside united states clinical development program mkb combination product extendedrelease niacin laropiprant simvastatin previously discontinue merck announce return global marketing development right intravenous oral formulation vernakalant treatment atrial fibrillation cardiome pharma corp business reason merck decide discontinue clinical development program mke combination product sitagliptin atorvastatin treatment type diabete business reason company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value approve medicine vaccine new indication new formulation important component company sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide small protein antibodie rnai merck move diversify portfolio biosimilar potential harness market opportunity present biological medicine patent expiry deliver high quality followon biologic product enhance access patient worldwide company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease insomnia neurodegenerative disease osteoporosis respiratory disease women health inprocess research development connection merger acquisition company record fair value incomplete research project time acquisition reach technological feasibility december balance iprd billion significant project latestage development include sugammadex sodium injection ezetimibeatorvastatin combination product currently review fda note vorapaxar remain phase iii clinical development table content approximately million million million respectively iprd project receive marketing approval major market company begin amortize asset base estimate useful life iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd acquisition date company recover research development expenditure acquisition develop program circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record million iprd impairment charge research development expense primarily pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value company record billion iprd impairment charge company determine development clinical research program vorapaxar constitute trigger event require company evaluate vorapaxar intangible asset impairment utilize market participant assumption consider different scenario company conclude good estimate current fair value intangible asset relate vorapaxar million result recognition impairment charge billion remain million iprd impairment charge record attributable compound abandon determine alternative use return respective licensor expect delay launch timing change cash flow assumption certain compound additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project acquire connection merger acquisition phase iii development human health analogous stage development animal health approximately billion acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth company complete transaction broad range therapeutic category include earlystage technology transaction merck actively monitor landscape growth opportunity meet company strategic criterion october merck aicuris enter exclusive licensing agreement provide merck worldwide right develop commercialize candidate aicuris novel portfolio investigational medicine target human cytomegalovirus hcmv include letermovir oral latestage antiviral candidate investigate treatment prevention hcmv infection transplant recipient aicuris receive upfront payment million approximately million company record research development expense eligible milestone payment million base successful achievement development regulatory commercialization goal hcmv candidate include letermovir additional backup candidate phase candidate design act table content alternate mechanism addition aicuris entitle receive royalty payment reflect advanced stage clinical program potential product result agreement merck responsible development activity cost agreement terminate party event material uncured breach insolvency agreement terminate merck time event compound license aicuris develop adverse safety profile material adverse issue arise related development efficacy dose regimen compound andor event certain patent invalid andor unenforceable certain jurisdiction merck terminate agreement respect certain compound successful completion proof concept clinical trial terminate agreement respect certain compound merck fails minimally invest compound addition merck terminate agreement time month prior write notice time completion phase iii clinical trial compound aicuris terminate agreement event merck challenge aicuris patent covering compound license aicuris termination agreement depend circumstance party vary right obligation respect continued development commercialization compound case termination cause merck certain royalty obligation april company enter agreement endocyte develop commercialize endocyte novel investigational therapeutic candidate vintafolide vintafolide currently evaluate phase iii clinical trial folatereceptor positive platinumresistant ovarian cancer proceed phase trial nonsmall cell lung cancer agreement merck gain worldwide right develop commercialize vintafolide endocyte receive million upfront payment company record research development expense eligible milestone payment million base successful achievement development regulatory commercialization goal vintafolide total cancer indication addition vintafolide receive regulatory approval merck endocyte share equally profit loss united states endocyte receive royalty sale product rest world endocyte retain right copromote vintafolide merck united states merck exclusive right promote vintafolide rest world endocyte responsible majority funding completion proceed trial merck responsible development activity development cost decision right vintafolide merck right terminate agreement day notice merck endocyte right terminate agreement material breach insolvency party endocyte right terminate agreement event merck challenge endocyte patent right relate vintafolide termination agreement depend circumstance party vary right obligation respect continued development commercialization vintafolide case termination cause merck certain royalty obligation profit loss share endocyte responsible development manufacture commercialization worldwide etarfolatide noninvasive companion diagnostic imaging agent identify folate receptor positive tumor cell discuss ema accept marketing authorization application filing vintafolide etarfolatide platinum resistant ovarian cancer select joint venture affiliate information expand research base realize synergy combine capability opportunity asset previous year merck form number joint venture astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange table content limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale kbi product revenue million billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest return aggregate million million million respectively conjunction restructuring discuss astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products april astrazeneca exercise asset option merck receive million astrazeneca represent net present value march project future pretax revenue receive merck nonppi products record reduction company investment azlp company recognize million defer income component income expense net addition merck grant astra option buy merck common stock interest kbi mercks interest nexium prilosec azlp exercisable june merck astrazeneca amend option agreement update agreement eliminate astrazenecas option acquire merck interest kbi provide astrazeneca new option acquire mercks interest kbi june result amend agreement merck continue record supply sale equity income partnership astrazeneca option purchase merck interest kbi base value merck interest nexium prilosec astrazenecas option exercisable march april astrazeneca choose exercise option closing date expect june amend agreement astrazeneca payment merck closing million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june exercise price include additional equal multiple time merck average annual profit allocation partnership year prior exercise company believe likely astrazeneca exercise option astrazeneca exercise option company long record equity income azlp supply sale azlp decline substantially sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million gardasil influenza vaccine viral vaccine rotateq hepatitis vaccine vaccine table content johnson johnsonmerck consumer pharmaceutical company september merck sell interest jjmcp joint venture venture merck form develop manufacture market distribute certain overthecounter consumer product united states canada merck receive onetime payment million recognize pretax gain million reflect income expense net partnership asset include manufacture facility sale product market joint venture million period january september divestiture date million capital expenditure capital expenditure billion billion billion expenditure united states billion billion million depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion cash provide operating activity reflect high contribution billion define benefit plan compare cash provide operating activity reflect payment million include interest relate resolution certain litigation relate vioxx increase cash provide operating activity compare reflect increase result operation partially offset million payment result arbitration settlement net payment approximately million internal revenue service irs result conclusion examination certain merck federal income tax return discuss cash provide operating activity continue company primary source fund finance operating need capital expenditure treasury stock purchase dividend pay shareholder global economic downturn sovereign debt issue factor adversely affect foreign receivables certain european country note consolidated financial statement company continue receive payment receivables include significant collection connection spanish government debt stabilizationstimulus plan additionally company continue expand emerge market payment term tend long condition emerge market result increase average length time take collect account receivable outstanding adversely affect cash provide operating activity table content cash investing activity billion compare billion primarily reflect high purchase security investment partially offset high proceed sale security investment cash investing activity billion compare billion primarily reflect high proceed sale security investment proceed disposition certain business partially offset high purchase security investment addition proceed astrazenecas asset option exercise decrease restrict asset contribute cash flow invest activity cash financing activity billion compare billion low use cash financing activity primarily drive proceed issuance debt low payment debt high proceed exercise stock option partially offset increase purchase treasury stock decrease shortterm borrowing high dividend pay stockholder cash financing activity billion compare billion high use cash financing activity primarily drive low proceed issuance debt high purchase treasury stock high payment debt partially offset increase shortterm borrowing effort implement merck strategy expand product offering capabilitie emerge market company anticipate future allocate capital resource region december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment generally cash investment hold foreign subsidiary subject significant tax payment cash investment repatriate form dividend company record defer tax liability certain unremitte earning amount earn overseas expect indefinitely reinveste outside united states accrual taxis provide cash investment hold foreign subsidiary fluctuate variety factor include time receipt payment normal course business cash provide operating activity united states continue company primary source fund finance domestic operating need capital expenditure treasury stock purchase dividend pay shareholder previously disclose canada revenue agency cra propose adjustment relate intercompany pricing matter july cra issue assessment miscellaneous audit issue tax year merck cra reach settlement year call merck pay additional canadian tax approximately million company unrecognized tax benefit relate matter exceed settlement company record net million tax provision benefit portion taxis pay expect creditable tax purpose company previously establish reserve matter resolution matter material effect company result operation financial position liquidity april irs conclude examination merck federal income tax return result company require net payment approximately million company unrecognized tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit net benefit reflect decrease unrecognized tax benefit year examination partially offset increase unrecognize tax benefit year subsequent examination period result settlement company disagree irs treatment issue raise examination appeal matter irs administrative process table content company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation enhance litigation settlement unrecognized tax benefit operating lease merck enter transaction require company future bulk supply purchase million maximum fouryear period commence occurrence certain predetermine event reflect table predetermine event occur time result payment give year determine discuss note consolidated financial statement company settle enhance litigation assume settlement approve court company anticipate pay million connection settlement company expect million recover insurance december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include million reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment exclude research development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million million respectively pension plan postretirement benefit plan company terminate exist credit facility enter new billion fiveyear credit facility mature facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility september company close underwritten public offer billion senior unsecured note consist billion aggregate principal note billion aggregate principal note million aggregate principal note interest note payable semiannually note series redeemable time company option vary redemption price proceed note general corporate purpose include contribution company pension plan repayment outstanding commercial paper certain debt maturity december company file security registration statement security exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date table content company longterm credit rating assign moodys investor service standard poor stable outlook stable outlook respectively rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november board director declare quarterly dividend share company common stock payable january april mercks board director approve additional purchase billion merck common stock treasury company purchase billion common stock million share treasury company approximately billion remain program treasury stock purchase time limit time open market block transaction privately negotiate transaction company purchase billion billion common stock respectively financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce table content upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow weak dollar result net benefit market value merck hedge decline estimate million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income taxis decline approximately million company net short position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange december company net long position relative major foreign currency consideration forward contract uniform strengthen dollar reduce income taxis approximately million measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow february venezuelan government devalue currency bolvar fuerte vef dollar vef dollar company anticipate recognize loss exchange approximately million quarter result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary table content result local foreign operation remeasure dollar impact record result operation addition effective january venezuelan government devalue currency twotiere official exchange rate essential rate nonessential rate december venezuelan government announce eliminate essential rate effective january result announcement company remeasure december monetary asset liabilitie new official rate company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment comprehensive income oci remain accumulated comprehensive income aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company terminate payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert certain fixedrate note floatingrate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate result swap termination company receive million cash include million accrue interest correspond million basis adjustment debt associate terminate interest rate swap contract defer amortize reduction interest expense respective term note cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion year percentage point decrease december negatively affect net aggregate market value billion year fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair table content value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record fair value intangible asset include acquire iprd determine utilize information available near merger acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset begin amortization judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate table content revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount customer collection account receivable expect excess year provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual follow millions balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch thecounter product product return provision pharmaceutical sale approximately net pharmaceutical sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program table content allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase iii clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent table content potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option pension postretirement benefit plan net periodic benefit cost pension postretirement benefit plan total million million million decline net periodic benefit cost pension postretirement benefit plan compare largely attributable benefit plan design change approve december note consolidated financial statement pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return range compare range pension postretirement benefit plan table content company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee amortization net loss companys plan december expect increase net periodic benefit cost approximately million annually restructure cost restructuring cost record connection restructuring program design reduce cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost market administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach table content goodwill represent excess consideration transfer fair value net asset business purchase assign reporting unit company test goodwill impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macro economic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price additionally company evaluate extent fair value exceed carry value reporting unit date valuation perform company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible exclude iprd record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company test iprd impairment annually frequently impairment indicator exist onestep test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operate result impairment investment company review investment impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthan temporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operates estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement table content financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability recently issue accounting standard july fasb issue amend guidance simplifie entity test indefinitelive intangible impairment amend guidance allow company assess qualitative factor determine morelikelythannot indefinitelive intangible asset impair basis determine necessary perform quantitative impairment test update guidance effective annual interim impairment test perform fiscal year begin september early adoption permit effect adoption company financial position result operation expect material cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive loss income net taxis net unrealized loss gain derivative net reclassification net unrealized gain loss investment net reclassification benefit plan net loss gain prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note defer income taxis current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share mandatory conversion convertible prefer stock treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge gain disposition interest equity method investment gain astrazeneca asset option exercise equity income affiliate dividend distribution equity affiliate defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment proceed sale interest equity method investment acquisition business net cash acquire disposition business net cash divest proceed astrazeneca asset option exercise decrease restrict asset net cash investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record table content foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain product await regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci decline fair value equity security consider thantemporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing table content software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin software project substantially complete asset ready intend use capitalize software cost associate company multiyear implementation enterprisewide resource planning system amortize year december approximately million million respectively remain unamortized capitalize software cost associate initiative capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business purchase goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform base company recent annual impairment test complete october company conclude goodwill impair acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note event circumstance warrant review company assess recoverability acquire intangible future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow inprocess research development inprocess research development iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life intangible asset generally determine period substantially cash flow expect generate begin amortization company test iprd impairment annually frequently impairment indicator exist onestep test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize operating result research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost period iprd impairment charge million million billion respectively sharebase compensation company expense sharebased payment employee requisite service period base grant date fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period table content contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard company retrospectively adopt amend guidance financial accounting standard board fasb presentation comprehensive income financial statement result adopt guidance company present separate statement comprehensive income adoption new guidance impact company financial position result operation cash flow recently issue accounting standard july fasb issue amend guidance simplifie entity test indefinitelive intangible impairment amend guidance allow company assess qualitative factor determine morelikelythannot indefinitelive intangible asset impair basis determine necessary perform quantitative impairment test update guidance effective annual interim impairment test perform fiscal year begin september early adoption permit effect adoption company financial position result operation expect material restructuring merger restructuring program subsequent merck scheringplough corporation scheringplough merger merger company commence action global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business design optimize cost structure combine company initial action expect result workforce reduction approximately primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility july company initiate action merger restructuring program company expect reduce workforce measure time merger additional company worldwide majority workforce reduction associate additional action relate manufacturing include animal health table content administrative headquarters organization company continue hire employee strategic growth area business necessary company record total pretax restructuring cost million billion billion relate program inception merger restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position restructure action merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate subsequent merger company rationalize number manufacture site worldwide remain action program result additional manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion billion increase original estimate primarily reflects accelerate depreciation relate additional facility closure identify company ongoing assessment worldwide capacity requirement manufacture research administrative facility subsequent merger include recently announce company worldwide headquarters summit new jersey company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest global restructuring program october merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy company worldwide pretax restructuring cost million million million record respectively relate restructuring program inception restructuring program december merck record total pretax accumulate cost billion eliminate approximately position comprise employee separation elimination contractor vacant position restructure program substantially complete exception certain manufacturingrelated action expect complete total cumulative pretax cost estimate billion company estimate twothird cumulative pretax cost relate cash outlay primarily employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest segment report restructuring charge unallocated expense table content follow table summarize charge related merger restructuring program restructuring program activity type cost separation accelerate year end december cost depreciation total merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative restructuring cost year end december merger restructuring program material production marketing administrative research development restructuring cost restructure program material production research development restructuring cost year end december merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative research development restructuring cost table content separation cost associate actual headcount reduction headcount reduction probable reasonably estimate approximately position respectively eliminate merger restructuring program approximately position respectively eliminate restructure program position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future cash flow sufficient recover respective book value merck require accelerate depreciation site asset write immediately anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include million million million respectively asset abandonment shutdown relate cost include approximately million contract termination cost additionally activity include million million million respectively employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan note sharebased compensation cost activity reflect net pretax gain result sale facility relate asset million million million respectively adjustment record amount material period follow table summarize charge spend relate merger restructuring program restructuring program activity separation accelerate cost depreciation total merger restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december cash outlay associate merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate expect substantially complete cash outlay associate remain restructure reserve restructure program primarily manufacturingrelate expect complete end table content legacy scheringplough program prior merger scheringplough commence productivity transformation program design reduce avoid cost increase productivity company record million million respectively accelerate depreciation cost include material production cost addition restructure cost reflect million net gain primarily relate sale manufacturing facility program substantially complete end acquisition divestiture research collaboration license agreement october merck aicuris enter exclusive licensing agreement provide merck worldwide right develop commercialize candidate aicuris novel portfolio investigational medicine target human cytomegalovirus hcmv include letermovir oral latestage antiviral candidate investigate treatment prevention hcmv infection transplant recipient aicuris receive upfront payment million approximately million company record research development expense eligible milestone payment million base successful achievement development regulatory commercialization goal hcmv candidate include letermovir additional backup candidate phase candidate design act alternate mechanism addition aicuris entitle receive royalty payment reflect advanced stage clinical program potential product result agreement merck responsible development activity cost agreement terminate party event material uncured breach insolvency agreement terminate merck time event compound license aicuris develop adverse safety profile material adverse issue arise related development efficacy dose regimen compound andor event certain patent invalid andor unenforceable certain jurisdiction merck terminate agreement respect certain compound successful completion proof concept clinical trial terminate agreement respect certain compound merck fails minimally invest compound addition merck terminate agreement time month prior write notice time completion phase iii clinical trial compound aicuris terminate agreement event merck challenge aicuris patent covering compound license aicuris termination agreement depend circumstance party vary right obligation respect continued development commercialization compound case termination cause merck certain royalty obligation april company enter agreement endocyte inc endocyte develop commercialize endocyte novel investigational therapeutic candidate vintafolide vintafolide currently evaluate phase iii clinical trial folatereceptor positive platinum resistant ovarian cancer proceed phase trial nonsmall cell lung cancer agreement merck gain worldwide right develop commercialize vintafolide endocyte receive million upfront payment company record research development expense eligible milestone payment million base successful achievement development regulatory commercialization goal vintafolide total cancer indication addition vintafolide receive regulatory approval merck endocyte share equally profit loss united states endocyte receive royalty sale product rest world endocyte retain right copromote vintafolide merck united states merck exclusive right promote vintafolide rest world endocyte responsible majority funding completion proceed trial merck responsible development activity development cost decision right vintafolide merck right terminate agreement day notice merck endocyte right terminate agreement material breach insolvency party endocyte right terminate agreement event merck challenge endocyte patent right relate vintafolide termination agreement depend circumstance party vary right obligation respect continued development commercialization vintafolide case termination cause merck certain royalty obligation profit loss sharing merck complete acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focus develop commercialize ophthalmic product term merger agreement merck acquire outstanding share common stock inspire price share table content cash total approximately million transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially purchase price allocate inspire product product right intangible asset relate deferred tax liability defer tax asset relate inspire net operating loss carryforward goodwill transaction close accordingly result operation acquire business include company result operation acquisition date pro forma financial information include inspire historical financial result significant compare company financial result march company sell merck biomanufacture network provider contract manufacturing development service biopharmaceutical industry wholly own merck fujifilm corporation fujifilm term agreement fujifilm purchase equity interest merck subsidiary own asset merck biomanufacture network comprise facility locate research triangle park north carolina billingham united kingdom agreement fujifilm merck commit purchase certain development manufacturing service fair value fujifilm threeyear period follow closing transaction transaction result gain million reflect income expense net collaborative arrangement company continue strategy establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound technology platform drive near longterm growth company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound new technology broad range therapeutic area arrangement include upfront payment royalty profit share payment contingent occurrence certain future event link success asset development expense reimbursement payment party cozaarhyzaar merck dupont nemour company dupont agree form longterm research marketing collaboration develop class therapeutic agent high blood pressure heart disease discover dupont call angiotensin receptor antagonist include cozaar hyzaar return merck provide dupont marketing right united states canada prescription medicine sinemet sinemet company regain global marketing right sinemet sinemet pursuant agreement dupont company exclusive licensing agreement market cozaar hyzaar return royalty profit share payment dupont agreement terminate december accordance term result termination agreement merck long share profit marketing cost relate sale cozaar hyzaar dupont separate agreement trademark cozaar hyzaar permanently transfer merck exchange merck pay trademark royalty dupont base sale cozaar hyzaar period years remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product outside united states japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille table content syringe result company marketing right product extend year commercial sale simponi european union follow receipt pricing reimbursement approval april merck reach agreement amend agreement govern distribution right remicade simponi term amend distribution agreement merck relinquish marketing right remicade simponi territory include canada central south america middle east africa asia pacific effective july merck retain exclusive marketing right europe russia turkey retain territory addition begin july profit derive merck exclusive distribution product retain territory equally divide merck receive onetime payment merck million april company record charge income expense net financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option table content value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness minimis derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci include cumulative translation adjustment pretax loss million pretax gain million million eurodenominate note table content interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company terminate payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert certain fixedrate note floatingrate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate result swap termination company receive million cash include million accrue interest correspond million basis adjustment debt associate terminate interest rate swap contract defer amortize reduction interest expense respective term note cash flow contract report operating activity consolidate statement cash flow present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative dollar derivative dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument foreign exchange contract current defer income taxis current asset foreign exchange contract noncurrent asset foreign exchange contract current accrue current liability foreign exchange contract defer income taxis noncurrent noncurrent liability derivative designate hedge instrument foreign exchange contract current defer income taxis current asset foreign exchange contract noncurrent asset foreign exchange contract current accrue current liability table content table provide information location pretax gain loss amount derivative designate fair value hedge relationship designate cash flow hedging relationship iii designate foreign currency net investment hedge relationship designate hedge relationship year end december derivative designate fair value hedge relationship interest rate swap contract gain recognize income expense net derivative loss recognize income expense net hedge item derivative designate foreign currency cash flow hedging relationship foreign exchange contract loss reclassify aoci sale loss gain recognize oci derivative derivative designate foreign currency net investment hedging relationship foreign exchange contract gain recognize income expense net derivative gain loss recognize oci deriviative derivative designate hedge relationship foreign exchange contract loss gain recognize income expense net derivative loss gain recognize sale ineffectiveness hedge represent exclude hedge effectiveness testing derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize loss derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information availableforsale investment december follow gross unrealized gross unrealize fair amortize fair amortize value cost gain loss value cost gain loss corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond debt security equity security availableforsale debt security include shortterm investment total billion december remain debt security billion mature year december debt security pledge collateral fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset investment corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security debt security asset security hold employee compensation derivative asset purchase currency option forward exchange contract total asset liability derivative liability forward exchange contract write currency option total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant transfer level level december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place table content instrument meet high credit quality standard specify company investment policy guideline approximately company cash cash equivalent invest highly rate money market fund majority company account receivable arise product sale united states europe primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor economic condition include volatility associate international sovereign economy associate impact financial market business take consideration global economic downturn sovereign debt issue certain european country company continue monitor credit economic condition greece italy spain portugal member economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding time value money discount record customer collection account receivable expect excess year december company classify approximately million account receivable expect collect year asset company expect writeoff adjustment account receivable material adverse effect financial position liquidity result operation december company account receivable greece italy spain portugal total approximately billion hospital public sector receivables approximately million aggregate approximately relate greece italy spain portugal respectively december company total account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables company collect approximately million account receivable government portugal pertain account receivable outstanding prior company collect approximately million account receivable connection spanish government debt stabilizationstimulus plan addition company complete nonrecourse factoring approximately million hospital public sector account receivable italy previously disclose company receive zero coupon bond greek government settlement receivables relate certain government sponsor institution company record impairment charge reduce bond fair value company sell portion bond remainder sell company continue receive payment greek hospital public sector receivables additionally company continue expand emerge market payment term market tend long result increase account receivable balance certain market company customer large account receivable balance cardinal health inc mckesson corporation amerisourcebergen corporation alliance healthcare zuellig pharma ltd asia pacific grupo casa saba mexico represent aggregate approximately onefourth total account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty december company receive cash collateral million million respectively counterpartie obligation return collateral record accrue current liability company advanced cash collateral counterpartie december table content inventory inventory december consist finished good raw material work process supply total approximate current cost increase reduction lifo cost recognize inventory asset inventory value lifo method comprise approximately inventory december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical total goodwill balance january addition goodwill balance december goodwill balance december include cumulative translation adjustment goodwill balance certain adjustment addition amount reflect reclassification goodwill pharmaceutical segment consumer care segment result segment change intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right inprocess research development tradename table content acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life company significant acquire intangible relate market product december include zetia billion vytorin billion nasonex billion claritin billion nuvare billion company record impairment charge million relate market product iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization million million respectively iprd reclassify product product right receipt marketing approval major market significant project latestage development include sugammadex sodium injection ezetimibeatorvastatin combination product currently review fda vorapaxar remain phase iii clinical development company record million iprd impairment charge research development expense primarily pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value company record billion iprd impairment charge research development expense billion relate writedown vorapaxar intangible asset company determine development clinical research program vorapaxar include termination clinical trial constitute trigger event require company evaluate vorapaxar intangible asset impairment company continue monitor remain million asset value vorapaxar impairment remain million iprd impairment charge record attributable compound abandon determine alternative use return respective licensor expect delay launch timing change cash flow assumption certain compound iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate aggregate amortization expense primarily record material production cost billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow year end december astrazeneca primarily reflect result sanofi pasteur msd johnson johnsonmerck consumer pharmaceutical company dispose september table content astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale kbi product revenue million billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest conjunction restructuring discuss astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products april astrazeneca exercise asset option merck receive million astrazeneca represent net present value march project future pretax revenue receive merck nonppi products record reduction company investment azlp company recognize million defer income component income expense net addition merck grant astra option buy merck common stock interest kbi mercks interest nexium prilosec azlp exercisable june merck astrazeneca amend option agreement update agreement eliminate astrazenecas option acquire merck interest kbi provide astrazeneca new option acquire mercks interest kbi june result amend agreement merck continue record supply sale equity income partnership astrazeneca option purchase merck interest kbi base value merck interest nexium prilosec astrazenecas option exercisable march april astrazeneca choose exercise option closing date expect june amend agreement astrazeneca payment merck closing million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june exercise price include additional equal multiple time merck average annual profit allocation partnership year prior exercise company believe likely astrazeneca exercise option table content summarize financial information azlp follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability merck partnership return azlp generally contractually determine note base percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion billion billion johnson johnsonmerck consumer pharmaceutical company september merck sell interest johnson johnsonmerck consumer pharmaceutical company jjmcp joint venture venture merck form develop manufacture market distribute certain overthecounter consumer product united states canada merck receive onetime payment million recognize pretax gain million reflect income expense net partnership asset include manufacture facility sale product market joint venture million period january september divestiture date million investment affiliate account equity method include joint venture total billion december million december amount report asset amount joint venture include defer income taxis current asset million december million december summarize information affiliate exclude azlp disclose separately follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability noncurrent liability include information jjmcp joint venture divestiture september table content loan payable longterm debt commitment loan payable december include billion note billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder loan payable december include billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing december respectively longterm debt december consist eurodenominate note note note note note note note note note note note note debenture note debenture note debenture note note present table include million million december respectively borrowing variable rate average include foreign borrowing million million december respectively vary rate exception debenture note list table redeemable merck option time vary redemption price september company close underwritten public offer billion senior unsecured note consist billion aggregate principal note billion aggregate principal note million aggregate principal note interest note payable semiannually note series redeemable time company option vary redemption price proceed note general corporate purpose include contribution company pension plan repayment outstanding commercial paper certain debt maturity connection merger effective november company execute unconditional guarantee exist debt subsidiary msd msd execute unconditional table content guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent merger certain company borrowing require merck comply financial covenant include requirement total debt capitalization ratio define applicable agreement exceed december company compliance covenant aggregate maturity longterm debt year follow billion billion billion million billion company terminate exist credit facility enter new billion fiveyear credit facility mature facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action environmental matter vioxx litigation define separate assessment provide note opinion company unlikely resolution matter material company financial position result operation cash flow give preliminary nature litigation discuss include vioxx litigation complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august vioxx litigation product liability lawsuit previously disclose merck defendant approximately federal state lawsuit vioxx product liability lawsuit allege personal injury economic loss result purchase use vioxx remain case coordinate multidistrict litigation district court eastern district louisiana vioxx mdl judge eldon fallon pende court putative class action purportedly bring behalf individual purchaser user vioxx seek reimbursement allege economic loss vioxx mdl table content proceed approximately class action remain june merck move strike class claim judgment pleading master complaint include abovereference case briefing motion complete september vioxx mdl court hear oral argument merck motion october take advisement missouri state court certify class missouri plaintiff seek reimbursement outofpocket cost relate vioxx october party execute settlement agreement resolve litigation company establish reserve million quarter connection settlement agreement minimum company require pay agreement court preliminarily approve agreement class notice claim program underway indiana plaintiff file motion certify class indiana vioxx purchaser case pende circuit court marion county indiana case dormant year april kentucky state court deny merck motion summary judgment certify class kentucky plaintiff seek reimbursement outofpocket cost relate vioxx trial court subsequently enter amend class certification order january merck appeal order kentucky court appeals february kentucky court appeal reverse trial court amend class certification order deny certification plaintiff petitioned kentucky supreme court review court appeal order november kentucky supreme court grant review brief kentucky supreme court underway merck name defendant lawsuit bring state attorney general state action kentucky action vioxx mdl proceeding action allege merck misrepresented safety vioxx suit seek recovery expenditure vioxx governmentfunde health care program medicaid andor penalty allege consumer fraud act violation kentucky action currently schedule proceed trial kentucky state court october january merck finalize settlement action file pennsylvania attorney general merck agree pay pennsylvania million exchange dismissal lawsuit shareholder lawsuit previously disclose addition vioxx product liability lawsuit putative class action individual lawsuit federal security law state law file merck current officer director vioxx security lawsuit vioxx security lawsuit coordinate multidistrict litigation district court district new jersey judge stanley chesler consolidated purpose august judge chesler grant deny merck motion dismiss fifth amend class action complaint consolidate security action thing claim base statement voluntary withdrawal vioxx september dismiss october defendant answer fifth amend class action complaint april plaintiff file motion class certification january judge chesler grant motion discovery currently proceed accordance court scheduling order previously disclose individual security lawsuit file foreign institutional investor consolidate vioxx security lawsuit october plaintiff file amend complaint pende individual security lawsuit october new individual security lawsuit kbc lawsuit file district new jersey foreign institutional investor case consolidate vioxx security lawsuit january defendant file motion dismiss individual lawsuit abp lawsuit briefing motion dismiss complete march august judge chesler grant deny motion dismiss abp lawsuit thing certain allege misstatement omission dismiss inactionable state law claim dismiss september defendant answer complaint individual action kbc lawsuit day defendant move dismiss complaint kbc lawsuit statute limitation ground december judge chesler deny motion dismiss kbc lawsuit january defendant answer complaint kbc lawsuit discovery currently proceed individual security lawsuit discovery class action table content insurance company director officer insurance coverage applicable vioxx security lawsuit remain state upper limit approximately million currently partially fund company legal fee result previously disclose insurance arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit international lawsuit previously disclose addition lawsuit discuss merck name defendant litigation relate vioxx australia brazil canada europe israel collectively vioxx international lawsuit previously disclose company enter agreement resolve claim relate vioxx canada pursuant company pay minimum approximately million aggregate maximum approximately million agreement pende approval court canadas province reserve company believe meritorious defense remain vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx lawsuit company establish reserve respect canadian settlement respect certain vioxx product liability lawsuit include missouri matter discuss company immaterial remain reserve relate previously disclose vioxx investigation nonparticipating state litigation continue company establish liability reserve respect vioxx litigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende merck federal state court include case seek class action certification damage andor medical monitoring approximately action plaintiff allege thing suffer osteonecrosis jaw onj generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax addition plaintiff approximately action generally allege sustained femur fracture andor bone injury femur fracture association use fosamax case allege onj andor jaw relate injury august judicial panel multidistrict litigation jpml order certain fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax onj mdl coordinated pretrial proceeding fosamax onj mdl transferred judge john keenan district court southern district new york result jpml order approximately case judge keenan fosamax onj mdl trial boles merck fosamax onj mdl court declare mistrial person jury reach unanimous verdict bole case retry june result verdict favor plaintiff million merck file posttrial motion seek judgment matter law alternative new trial october court deny merck posttrial motion sua sponte order remittitur reduce table content verdict million plaintiff reject remittitur order court request new trial damage plaintiff merck subsequently enter confidential stipulation plaintiff damage enable merck appeal underlie judgment merck file appeal bole case october prior case try verdict fosamax onj mdl defense verdict favor merck return case plaintiff file appeal case grave merck secrest merck january court appeal second circuit affirm judgment merck favor secrest february judge keenan order bellwether trial conduct fosamax onj mdl spano merck jellema merck select court try case dismiss plaintiff march court select scheinberg merck case try trial scheinberg case begin january february jury return mixed verdict find favor merck plaintiff design defect claim find favor plaintiff failure warn claim award thousand compensatory damage outside fosamax onj mdl florida carballo merck set trial october plaintiff dismiss case refile fosamax onj mdl anderson merck set trial january plaintiff dismiss case prior trial addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seeking damage exist dental jaw relate injury include onj solely seek medical monitoring designate mass tort centralize management purpose judge carol higbee atlantic county superior court december approximately onj case pende merck atlantic county new jersey july judge higbee enter case management order amendment thereto set forth schedule contemplate complete fact expert discovery initial group case review trial february jury rosenberg merck trial new jersey coordinated proceeding return verdict merck favor april jury sessner merck second case try new jersey return verdict merck favor plaintiff file appeal case california party review claim plaintiff carrie smith merck case claim pedrojetti merck case plaintiff try discovery ongoing fosamax onj mdl litigation new jersey coordinated proceed remain jurisdiction fosamax onj case pende company intend defend lawsuit case allege femur fracture march merck submit motion transfer jpml seek federal case allege femur fracture consolidate multidistrict litigation coordinate pretrial proceeding motion transfer grant federal case involve allegation femur fracture transfer multidistrict litigation district new jersey fosamax femur fracture mdl result jpml order approximately case pende fosamax femur fracture mdl december case management order enter require party review case later reduce case judge joel pisano select case group try initial bellwether case fosamax femur fracture mdl set april trial date bellwether case glynn merck zessin merck case set try september young merck case set try january johnson merck case set try december approximately case allege femur fracture file new jersey state court pending judge higbee atlantic county superior court party select initial group case review fact discovery judge higbee set march date trial new jersey state femur fracture case merck table content december approximately case allege femur fracture file california state court petition file seek coordinate femur fracture case file california state court single judge orange county california petition grant judge steven perk preside coordinate proceeding scheduling order enter additionally femur fracture case pende state court trial date set august barne merck case pende alabama state court discovery ongoing fosamax femur fracture mdl state court femur fracture case pende company intend defend lawsuit nuvare previously disclose beginning number complaint file jurisdiction assert claim company subsidiarie organon usa inc organon pharmaceuticals usa inc organon international collectively organon company arise organon marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon scheringplough thing fail adequately design manufacture nuvare fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation nuvaring mdl venue missouri coordinated proceed new jersey state court december approximately nuvare case case approximately pende nuvare mdl district court eastern district missouri judge rodney sippel approximately pende coordinated discovery proceeding bergen county superior court new jersey judge brian martinotti additional case pende state court pursuant order judge sippel nuvare mdl party originally select pool case prepare trial pool narrow case trial nuvare mdl select nuvare mdl trial expect place summer pursuant judge martinottis order new jersey proceeding party select trial pool case prepare trial trial expect commence party complete fact discovery originally select trial pool case jurisdiction expert discovery complete trial pool case certain replacement trial pool case remain fact discovery company file motion relate admissibility expert testimony motion summary judgment company expect substantive hearing motion summary judgment place new jersey case early follow substantive hearing admissibility expert testimony resolution summary judgment motion company expect substantive hearing motion summary judgment nuvare mdl case place spring follow hearing admissibility expert testimony company certain insurance coverage available currently partially fund company legal fee company intend defend lawsuit propeciaproscar previously disclose merck defendant product liability lawsuit unite states involve propecia andor proscar december approximately lawsuit involve total approximately plaintiff instance spouse join suit allege experience persistent sexual effect follow cessation treatment propecia andor proscar file merck lawsuit early stage file federal court state court new jersey federal lawsuit consolidate pretrial purpose federal mdl judge john gleeson eastern district new york matter pende state court new jersey consolidated judge jessica mayer middlesex county company intend defend lawsuit table content vytorinzetia litigation previously disclose april merck shareholder file putative class action lawsuit federal court consolidated district new jersey federal security lawsuit caption merck inc vytorin security litigation amend consolidated complaint file october name defendant merck merckscheringplough pharmaceutical llc certain company current officer director complaint allege merck delay release unfavorable result enhance clinical trial efficacy vytorin merck false misleading statement expect earning know result enhance study release sale vytorin decline merck earning suffer december merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court deny defendant motion dismiss march defendant file motion summary judgment september court grant lead plaintiff amend motion class certification deny defendant motion summary judgment february merck announce reach agreement principle plaintiff settle matter million settlement subject court approval propose settlement reflect company financial result discuss similar consolidated putative class action security lawsuit pende district new jersey file scheringplough shareholder scheringplough chairman president chief executive officer fre hassan caption scheringplough corporationenhance security litigation amend consolidated complaint file september name defendant scheringplough merckscheringplough pharmaceutical llc certain company current officer director underwriter participate august public offering scheringplough common prefer stock december scheringplough defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant september court deny defendant motion dismiss march scheringplough defendant file motion partial summary judgment underwriter defendant file motion summary judgment september court grant lead plaintiff amend motion class certification deny defendant motion summary judgment february merck announce reach agreement principle plaintiff settle matter million settlement subject court approval approve settlement exhaust remain director officer insurance coverage applicable vytorin lawsuit bring legacy scheringplough shareholder propose settlement reflect company financial result settlement describe precede paragraph result aggregate charge million take account anticipate insurance recovery million governmental proceeding previously disclose merck receive civil investigative demand cid issue department justice doj address inspire company acquire merck cid advise relate false claim act investigation concern allegation inspire cause submission false claim federal health benefit program drug azasite marketing treatment indication approve fda company cooperate doj investigation previously disclose company receive subpoena attorney office eastern district california request information civil federal health care investigation relate company marketing selling activity respect integrilin avelox january june december district court eastern district california unseal complaint employee company file federal false claim act false claim act state complaint allege company cause false claim federal state health care program promote integrilin unapproved indication provide unlawful payment benefit physician increase utilization integrilin avelox federal government state statute suit file right investigate allegation intervene suit assume responsibility direction notify court decline intervene company intend defend suit table content company previously disclose receive subpoena request information relate company marketing selling activity respect temodar pegintron intron january present federal health care investigation criminal statute company inform attorney office district massachusetts subpoena enforce action company require previously disclose company receive letter doj sec seek information activity number country reference foreign corrupt practice act company cooperate agency request believe inquiry broad review pharmaceutical industry practice foreign country regard company receive continue receive additional request information doj sec previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition putative class action lawsuit file company eastern district pennsylvania behalf direct purchaser mmr vaccine predicate allegation false claim act complaint charge company misrepresented efficacy mmr vaccine violation federal antitrust law state consumer protection law company intend defend lawsuit commercial litigation awp litigation previously disclose company andor certain subsidiary remain defendant case bring state allege manipulation pharmaceutical manufacturer average wholesale price awp public private payor calculate provider reimbursement level outcome lawsuit include substantial damage imposition substantial fine penalty injunctive administrative remedy start company settle certain awp case bring states alabama alaska kansas kentucky louisiana oklahoma mississippi company andor certain subsidiary continue defendant case bring state company reinstate defendant putative class action new jersey superior court allege behalf thirdparty payer individual manufacturer inflate drug price manipulation awps mean case originally dismiss company prejudice company intend defend lawsuit kdur antitrust litigation previously disclose june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application anda follow commencement administrative proceed federal trade commission ftc allege anticompetitive effect settlement resolve schering plough favor putative class nonclass action suit file behalf direct indirect purchaser kdur scheringplough upshersmith lederle consolidated multidistrict litigation district court district new jersey suit claim violation federal state antitrust law state statutory common law cause action seek unspecified damage april indirect purchaser voluntarily dismiss case march district court grant summary judgment defendant remain lawsuit dismiss matter entirety july circuit table content court appeal reverse district court judgment remand case proceeding time circuit uphold december decision district court certify certain direct purchaser plaintiff claim class action august company file petition certiorari supreme court seek review circuit reversal summary judgment supreme court take action petition december grant certiorari unrelated case circuit court appeal reach decision appear conflict circuit hold company case company expect issue seek raise supreme court resolve supreme court pende decision circuit case nexium antitrust litigation previously disclose september company certain subsidiary defendant name putative class action lawsuit bring behalf direct purchaser nexium federal court new jersey lawsuit allege violation federal antitrust law arise settlement reach defendant resolve certain patent litigation relate entry generic esomeprazole market specifically plaintiff contend settlement effect impermissibly delay entry generic esomeprazole united states extend monopoly power nexium lead high average market price january company subsidiary dismiss prejudice lawsuit coupon litigation previously disclose march number private health plan file separate putative class action lawsuit company allege merck coupon program injure health insurer reduce beneficiary copayment amount allegedly cause beneficiary purchase higherpriced drug purchase increase insurer reimbursement cost action pende district court district new jersey seek damage injunctive relief bar company issue coupon reduce beneficiary pay behalf putative nationwide class health insurer similar action relate manufacturer coupon program file pharmaceutical manufacturer variety federal court company intend defend lawsuit patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company certain product company market agreement company currently involve patent infringement litigation united states include azasite emend injection integrilin nasonex nexium vytorin zetia similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire merger acquisition potentially significant intangible asset impairment charge azasite patent infringement lawsuit file united states sandoz inc sandoz respect sandozs application fda seek prepatent expiry approval market generic version azasite lawsuit automatically stay fda approval sandozs anda october adverse court decision whichever occur early emend injection patent infringement lawsuit file united states sandoz respect sandozs application fda seek prepatent expiry approval market generic version emend injection lawsuit automatically stay fda approval sandozs anda july adverse court decision whichever occur early june patent infringement lawsuit file united states accord healthcare inc accord healthcare inc intas table content pharmaceuticals ltd collectively inta respect intas application fda seek prepatent expiry approval market generic version emend injection lawsuit automatically stay fda approval intas anda july adverse court decision whichever occur early integrilin february patent infringement lawsuit file jointly millennium pharmaceuticals inc united states teva parenteral medicines inc tpm respect tpm application fda seek approval sell generic version integrilin prior expiry expire list patent october party enter settlement agreement allow tpm sell generic version integrilin begin june november patent infringement lawsuit file app pharmaceutical inc fresenius kabi usa inc collectively app respect app application fda seek approval sell generic version integrilin prior expiry expire list patent lawsuit automatically stay fda approval apps anda april adverse court decision whichever occur early nasonex december patent infringement lawsuit file united states apotex corp apotex respect apotexs application fda seek prepatent expiry approval market generic version nasonex trial matter hold april decision issue june holding merck patent cover mometasone furoate monohydrate valid infringe apotexs propose product find noninfringement appeal nexium patent infringement lawsuit bring jointly astrazeneca united states follow generic company ranbaxy laboratories ltd ivax pharmaceuticals inc later acquire teva pharmaceuticals inc teva reddys laboratories sandoz lupin ltd hetero drugs limited unit iii torrent pharmaceuticals ltd response generic company application seek prepatent expiry approval sell generic version nexium settlement reach lawsuit term provide respective generic company bring generic version esomeprazole product market addition patent infringement lawsuit file jointly astrazeneca february united states sun pharma global fze sun pharma respect application fda seek prepatent expiry approval sell generic version nexium lawsuit settle agreement provide sun pharma entitle bring generic esomeprazole product market united states january finally additional patent infringement lawsuit file jointly astrazeneca united states hamni usa inc hamni mylan laboratories limited mylan labs relate application fda seek prepatent expiry approval sell generic version nexium hamni mylan labs application fda remain stay august respectively early adverse court decision whichever occur early vytorin december patent infringement lawsuit file united states mylan pharmaceuticals inc mylan respect mylan application fda seek prepatent expiry approval sell generic version vytorin trial mylan jointly respect zetia vytorin conduct december april court issue decision find patent valid enforceable accordingly mylans anda approvable april february court appeal federal circuit affirm low court decision february patent infringement lawsuit file united states teva respect tevas application fda seek prepatent expiry approval sell generic version vytorin july patent infringement lawsuit dismiss teva agree sell generic version zetia vytorin companys exclusivity right expire april certain circumstance august patent infringement lawsuit file united states impax laboratories inc impax respect impaxs application fda seek prepatent expiry approval sell generic version vytorin agreement reach impax stay lawsuit pende outcome lawsuit mylan october patent infringement lawsuit file united states actavis inc actavis respect actavis application fda seek prepatent expiry approval sell generic version vytorin agreement reach actavis stay lawsuit pende outcome lawsuit mylan zetia march patent infringement lawsuit file united states glenmark pharmaceuticals inc usa parent corporation collectively glenmark respect glenmark application fda seek prepatent expiry approval sell generic version zetia table content glenmark agree settlement virtue glenmark permit launch generic product united states december subject receive final fda approval june patent infringement lawsuit file united states mylan respect mylan application fda seek prepatent expiry approval sell generic version zetia trial mylan jointly respect zetia vytorin conduct december april court issue decision find patent valid enforceable accordingly mylans anda approvable april february court appeal federal circuit affirm low court decision september patent infringement lawsuit file united states teva respect tevas application fda seek prepatent expiry approval sell generic version zetia july patent infringement lawsuit dismiss right grant teva september patent infringement suit file united states sandoz respect sandozs application fda seek prepatent expiry approval market generic version zetia lawsuit automatically stay fda approval sandozs anda february adverse court decision whichever occur early environmental litigation previously disclose approximately plaintiff file amend complaint merck defendant district court eastern district california assert claim clean water act resource conservation recovery act negligence nuisance suit seek damage personal injury diminution property value medical monitoring allege real personal property damage associate groundwater surface water soil contamination find site merck subsidiary merce california certain defendant suit settle plaintiff aspect plaintiff claim lawsuit proceeding phase manner jury trial commence february jury ask certain factual finding contamination move offsite area plaintiff expose contamination amount defendant phase trial include merck original defendant march phase jury return mixed verdict find favor merck defendant plaintiff claim specifically jury find contamination site enter affect plaintiff municipal water supply well private domestic well jury find plaintiff expose contamination air emission prior surface water form storm drainage channel adjacent irrigation canal include flood april response posttrial motion merck defendant september court enter order set aside phase jury finding favor plaintiff specifically court hold plaintiff expose contamination surface flood water april flood fact time later merck motion reconsideration remainder jurys phase verdict adverse merck deny follow retirement judge handle case september case assign judge david carter district court central district california judge carter select plaintiff claim review depend outcome merck summary judgment motion possibly try early plaintiff subsequently withdraw claim plaintiff leave claim proceed trial court dismiss claim plaintiff action claim preclude aspect phase jury finding court subsequent order subject court anticipate ruling defendant potentially dispositive summary judgment pretrial motion trial select trial plaintiff claim anticipate begin near end march litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial position result operation cash flow individually aggregate table content legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year equity merck certificate incorporation authorize share common stock share prefer stock authorize share prefer stock series share designate mandatory convertible preferred stock table content capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuances mandatory conversion convertible prefer stock balance december issuance primarily reflect activity sharebase compensation plan remain outstanding mandatory convertible preferred stock convert connection merger automatically convert term right receive cash share merck common stock result conversion approximately million pay holder approximately million merck common share issue noncontrolle interest connection restructure ami merck assume billion par value prefer stock dividend rate annum carry kbi include noncontrolle interest astrazeneca exercise option acquire mercks interest azlp note preferred stock obligation retire sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle primarily treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus certain psus grant december employee participate dividend basis common share dividend nonforfeitable holder rsus psus issue january dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield risk table content free interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term value outstanding january grant exercise forfeit outstanding december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december table content december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary december compensation benefit committee company board director approve management proposal change merck primary define benefit pension plan benefit formula cash balance formula begin service january active participant plan december accrue pension benefit prospectively new cash balance formula base age service pay interest transition period january december participant earn great benefit calculate employee legacy final average pay formula new cash balance formula year service december participant earn future benefit cash balance formula addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan december company approve change retiree healthcare plan include change certain employee contribution subsidy level eligibility criterion subsidize retiree medical coverage elimination certain retiree dental coverage company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost pension postretirement benefit plan consist follow component pension benefit postretirement benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net periodic benefit cost decline net periodic benefit cost pension postretirement benefit plan compare largely attributable benefit plan design change discuss change merck primary define benefit pension plan retiree healthcare plan reduce benefit obligation december million million respectively correspond offset aoci amortize reduction net periodic benefit cost employee future service period approximately year net periodic benefit cost attributable pension plan include table million million million connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan addition settlement record certain domestic international pension plan table content obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow postretirement pension benefit benefit fair value plan asset january actual return plan asset company contribution merger acquisition divestiture effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost merger acquisition divestiture actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability defer income taxis noncurrent liability table content fair value pension plan asset include precede table billion billion december respectively project benefit obligation pension plan billion billion respectively approximately company pension project benefit obligation december respectively relate international define benefit plan individual plan significant relative total project benefit obligation december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan pension plan project benefit obligation excess plan asset december fair value plan asset billion billion respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset billion billion respectively accumulate benefit obligation billion billion respectively plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment year end categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund large cap equitie smallmid cap equity nonus develop market equity nonus emerge market equity government agency obligation corporate obligation fix income obligation real estate equity security large cap smallmid cap nonus develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract derivative liability derivative plan level investment real estate fund generally value market appraisal underlie investment fund plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total balance january actual return plan asset relate asset hold december relate asset sell year purchase sale transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund large cap equitie smallmid cap equity nonus develop market equity nonus emerge market equity fix income obligation equity security large cap smallmid cap nonus develop market fix income security government agency obligation corporate obligation mortgage assetbacked security fix income obligation company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard table content deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution contribution pension plan postretirement benefit plan expect approximately million million respectively expect benefit payment expect benefit payment follow pension postretirement benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component oci postretirement pension plan benefit plan year end december net loss gain arise period prior service cost credit arise period net loss amortization include benefit cost prior service credit cost amortization include benefit cost estimate net loss gain prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension plan pension postretirement benefit plan information follow pension pension plan postretirement benefit plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determined country basis develop expect rate return country longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return countrys target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return range compare range pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net year end december interest income interest expense exchange loss net increase interest income compare reflect accretion time value money discount relate certain account receivables include accelerate accretion relate significant collection account receivable spain note increase interest income compare primarily reflect high average investment balance exchange loss reflect million loss venezuelan currency devaluation discuss net present table reflect million net charge relate settlement enhance litigation note net reflect million charge relate resolution arbitration proceeding involve company right market remicade simponi note million gain disposition company interest jjmcp joint venture note million gain sale certain manufacturing facility relate asset note net reflect million charge settle certain vioxx litigation charge relate settlement certain pende awp litigation partially offset million income recognize astrazenecas asset option exercise note million income recognize settlement certain dispute royalty january company require remeasure local currency operation venezuela dollar venezuelan economy determine hyperinflationary addition note exchange loss reflect loss relate venezuelan currency devaluation effective january venezuelan government devalue currency twotiere official exchange rate essential rate nonessential rate december venezuelan government announce eliminate essential rate effective january result announcement company remeasure december monetary asset liabilitie new official rate interest pay million million million exclude commitment fee interest pay net million receive company termination certain interest rate swap contract year note table content tax income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning tax settlement unremitte foreign earning amortization purchase accounting adjustment vioxx enhance litigation settlement restructure health care reform legislation tax rate change iprd impairment charge arbitration settlement charge state taxis include tax effect contingency reserve research credit miscellaneous item foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate unite states particularly singapore ireland switzerland puerto rico operate tax incentive grant earning indefinitely reinveste yield favorable impact effective tax rate compare statutory rate foreign earning tax rate differential include impact iprd impairment charge amortization purchase accounting adjustment restructure cost arbitration settlement charge item present separately represent significant separately disclose pretax cost charge substantial portion item relate jurisdiction low tax rate united states impact record expense item low tax rate jurisdiction unfavorable impact effective tax rate compare statutory rate income taxis consist year end december domestic foreign table content taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize deferred income taxis current asset asset income taxis payable deferred income taxis noncurrent liability company net operating loss nol carryforward jurisdiction december approximately million defer taxis nol carryforward relate foreign jurisdiction individually significant approximately million valuation allowance establish foreign nol carryforward addition company approximately million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry table content income taxis pay billion billion billion respectively tax benefit relate stock option exercise reflect paidin capital million amount material reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december reflect settlement cra discuss reflect conclusion irs examination merck federal income tax return resolution interest rate swap dispute irs discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount benefit expense million million million liability accrue interest penaltie billion billion december respectively previously disclose canada revenue agency cra propose adjustment relate intercompany pricing matter july cra issue assessment miscellaneous audit issue tax year merck cra reach settlement year call merck pay additional canadian tax approximately million company unrecognized tax benefit relate matter exceed settlement company record net million tax provision benefit portion taxis pay expect creditable tax purpose company previously establish reserve matter resolution matter material effect company result operation financial position liquidity april internal revenue service irs conclude examination merck federal income tax return result company require net payment approximately million company unrecognized tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit net benefit reflect decrease unrecognized tax benefit year examination partially offset increase unrecognize tax benefit year subsequent examination period result settlement company disagree irs treatment issue raise examination appeal matter irs administrative process irs finalize examination scheringplough tax year audit cycle company reach agreement irs adjustment income relate intercompany pricing matter income adjustment reduce nols tax credit carryforward additionally company seek resolution issue raise examination irs administrative appeal process company reserve uncertain tax position adequate cover adjustment relate examination period irs begin examination tax year table content addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant begin expire earning share company calculate earning share pursuant twoclass method earning allocation formula determine earning share common stock participate security accord dividend declare participation right undistribute earning method earning distribute undistributed allocate common share participate security base respective right receive dividend rsus certain psus grant december certain management level employee note participate dividend basis common share dividend nonforfeitable holder result rsus psus meet definition participate security rsus psus issue january dividend declare vest period payable employee vest rsus psus meet definition participate security calculation earning share twoclass method follow year end december basic earning common share net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding earning common share assume dilution net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive loss income component comprehensive loss income follow pretax tax tax year end december net unrealized loss derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net loss gain prior service credit cost net amortization cumulative translation adjustment year end december net unrealized loss derivative net loss realization derivative net unrealized loss investment net gain realization investment benefit plan net loss gain prior service credit cost net amortization cumulative translation adjustment year end december net unrealized gain derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net gain loss prior service cost credit net amortization cumulative translation adjustment include cumulative translation adjustment pretax gain loss approximately million billion respectively relate translation impact intangible asset record conjunction merger table content component accumulate comprehensive loss follow december net unrealized loss gain derivative net unrealized gain investment pension plan net loss postretirement benefit plan net loss pension plan prior service credit postretirement benefit plan prior service credit cumulative translation adjustment segment reporting company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance include revenue equity income company relationship azlp animal health consumer care alliance segment material separate reporting include table pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel accounting policy segment describe describe note table content sale company product follow primary care women health cardiovascular zetia vytorin diabetes obesity januvia janumet respiratory singulair nasonex clarinex dulera asmanex womens health endocrine fosamax nuvare follistim implanon cerazette maxalt arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress pegintron cancida victrelis invanz primaxin noxafil oncology temodar emend cosopttrusopt bridion integrilin diversify brand cozaarhyzaar propecia zocor claritin remeron proscar vasotecvaseretic vaccine gardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health consumer care alliance alliance segment include revenue company relationship azlp revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content consolidated revenues geographic area derive follow year end december united states europe middle east africa japan reconciliation total segment profit consolidate income taxis follow year end december segment profit pharmaceutical segment segment total segment profit profit loss unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment restructure cost net charge relate settlement enhance litigation arbitration settlement charge vioxx liability reserve gain astrazeneca asset option exercise unallocated net segment profit comprise segment sale standard cost certain operating expense directly incur segment internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit loss primarily comprise miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale unallocated net include expense corporate manufacturing cost center product intangible asset impairment charge gain loss sale business miscellaneous income expense item table content equity income affiliate depreciation amortization include segment profit follow pharmaceutical total year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization property plant equipment net geographic area locate follow year end december united states europe middle east africa japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck inc opinion accompany consolidated balance sheet relate consolidated statement income comprehensive income equity cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion merck maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso merck management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement merck internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder amount include net charge relate litigation settlement note amount include net benefit relate settlement federal income tax audit note amount include charge relate resolution arbitration proceeding note amount reflect acquisitionrelated cost note impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training include financial stewardship training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing table content management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier peter kellogg chairman president executive vice president chief executive officer chief financial officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutcodeofconductpdf merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior print copy send charge shareholder request write chief ethic compliance officer merck inc merck drive whitehouse station require information identification audit committee audit committee financial expert incorporate reference discussion head board committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation relate table potential payment termination change control include discussion subheading separation individual agreement change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold item securityownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan set forth document information respect security ownership certain beneficial owner management incorporate reference discussion head security ownership certain beneficial owner management company proxy statement annual meeting shareholder hold item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold table content require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion audit committee beginning caption pre approval policy service independent register public accounting firm fee companys proxy statement annual meeting shareholder hold item